clopidogrel and thiophenes

clopidogrel has been researched along with thiophenes in 538 studies

Research

Studies (538)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	138 (25.65)	29.6817
2010's	393 (73.05)	24.3611
2020's	7 (1.30)	2.80

Authors

Authors	Studies
Asai, F; Inoue, T; Koike, H; Ogawa, T; Sugidachi, A	1
Asai, F; Jakubowski, JA; Niitsu, Y; Sugidachi, A	1
Antman, EM; Behounek, BD; Braunwald, E; Carney, RJ; Lazzam, C; McCabe, CH; McKay, RG; Murphy, SA; Weerakkody, G; Winters, KJ; Wiviott, SD	1
Brandt, JT; Darstein, C; Jakubowski, JA; Jernberg, T; Naganuma, H; Payne, CD; Siegbahn, A; Wallentin, L; Winters, KJ	1
Lowry, DR; Malinin, AI; Meilman, H; Midei, MG; Serebruany, VL	1
Serebruany, VL	8
Antman, EM; Braunwald, E; Gibson, CM; McCabe, CH; Montalescot, G; Riesmeyer, J; Warmke, JW; Weerakkody, G; Winters, KJ; Wiviott, SD	1
Gurbel, PA; Tantry, US	1
Asai, F; Brandt, JT; Freestone, S; Hirota, T; Jakubowski, JA; Matsushima, N; Naganuma, H; Winters, KJ	1
Bliden, KP; Gurbel, PA; Tantry, US	1
Brandt, JT; Farid, NA; Jakubowski, JA; Naganuma, H; Payne, CD; Small, DS; Weerakkody, G; Winters, KJ; Wiviott, SD	1
Cattaneo, M	5
Araki, H; Batory, LA; McInnis, CE; Njardarson, JT; Rogers, E	1
Huber, K; Schrör, K; Siller-Matula, J; Wojta, J	1
Brandt, JT; Darstein, C; Ernest, CS; Farid, NA; Jakubowski, JA; Payne, CD; Salazar, DE; Small, DS; Winters, KJ	1
Brandt, JT; Farid, NA; Jakubowski, JA; Lachno, DR; Li, YG; Naganuma, H; Payne, CD; Weerakkody, GJ; Winters, KJ	1
Asai, F; Hagihara, K; Hashimoto, M; Jakubowski, JA; Kurihara, A; Niitsu, Y; Ogawa, T; Sugidachi, A	1
Brandt, JT; Farid, NA; Jakubowski, JA; Naganuma, H; Payne, CD; Warner, MR; Weerakkody, GJ; Winters, KJ; Zhu, J	1
Brandt, JT; Jakubowski, JA; Naganuma, H; Payne, CD; Weerakkody, GJ; Winters, KJ	1
de Lemos, JA; Wiviott, SD	1
Brandt, JT; Close, SL; Ernest, CS; Farid, NA; Iturria, SJ; Lachno, DR; Payne, CD; Salazar, D; Winters, KJ	1
Antman, EM; Ardissino, D; Braunwald, E; De Servi, S; Gibson, CM; Gottlieb, S; McCabe, CH; Montalescot, G; Murphy, SA; Neumann, FJ; Riesmeyer, J; Ruzyllo, W; Weerakkody, G; Wiviott, SD	1
Bhatt, DL	1
Asai, F; Hashimoto, M; Isobe, T; Jakubowski, JA; Niitsu, Y; Ogawa, T; Otsuguro, K; Sugidachi, A	1
Brandt, JT; Ernest, CS; Farid, NA; Jakubowski, JA; Li, YG; Payne, CD; Salazar, DE; Small, DS; Winters, KJ	1
Braun, OO; Erlinge, D; Jakubowski, JA; James, S; Siegbahn, A; Sugidachi, A; Varenhorst, C; Wallentin, L; Winters, KJ	1
Angiolillo, DJ; Antman, EM; Braunwald, E; Cairns, R; Frelinger, AL; Hod, H; Jakubowski, JA; McCabe, CH; Michelson, AD; Miller, DL; Montalescot, G; Murphy, SA; Neumann, FJ; O'Donoghue, M; Trenk, D; Wiviott, SD	1
Huber, K; Schrör, K	1
Angiolillo, DJ	1
Brandt, JT; Farid, NA; Jakubowski, JA; Li, YG; Payne, CD; Salazar, DE; Small, DS; Winters, KJ	3
Buckland, RJ; Jakubowski, JA; Judge, HM; Storey, RF; Sugidachi, A	1
Brandt, JT; Farid, NA; Li, YG; Payne, CD; Salazar, DE; Small, DS; Weerakkody, GJ; Winters, KJ	1
Schaerlig, E	1
Serebruany, V	2
Di Sciascio, G; Pasceri, V; Patti, G	1
Paulus, W; Riggert, J; von Lewinski, F	1
Antman, EM; Braunwald, E; Downey, WE; Herrman, JP; Horvath, I; Keltai, M; McCabe, CH; Murphy, SA; Scirica, BM; Van de Werf, F; Wiviott, SD	1
Eikelboom, JW; Hankey, GJ; Langton, PE	1
De Servi, S; Lettino, M	1
Ajani, AE; Lefkovits, J	1
Antman, EM; Braunwald, E; Murphy, SA; Wiviott, SD	1
Dovlatova, NL; Heptinstall, S; Jakubowski, JA; Sugidachi, A	1
Antman, EM; Braunwald, E; Chandna, H; Hasin, Y; Macias, W; McCabe, CH; Murphy, SA; Voitk, J; Widimsky, P; Wiviott, SD	1
Alvarez, W	1
Haber, SL; Riley, AB; Tafreshi, MJ	1
Dovlatova, N; Heptinstall, S; Johnson, A	1
Alberts, MJ; Hanley, DF; Serebruany, VL	1
Barker, CM; Price, MJ	1
Sosnowski, C	1
Antman, EM; Braunwald, E; Huber, K; Lopez-Sendon, J; McCabe, CH; Morocutti, G; Murphy, SA; Weerakkody, G; Wiviott, SD	1
Ramaraj, R	1
Cohen, M; Giugliano, R; Granger, CB; Gurbel, PA; Hoekstra, J; Hollander, JE; Manoukian, SV; Pollack, CV; Saucedo, JF	1
Angiolillo, DJ; Antman, EM; Braunwald, E; Corbalan, R; Dalby, AJ; Goodman, SG; McCabe, CH; Meisel, S; Murphy, SA; Purdy, DA; Verheugt, FW; Wiviott, SD	1
Ernest, CS; Farid, NA; Li, YG; Payne, CD; Salazar, DE; Small, DS; Winters, KJ	1
Preobrazhenskiĭ, DV	1
Klauss, V; Krötz, F; Sohn, HY	1
Brandt, JT; Braun, OO; Erlinge, D; Jakubowski, JA; James, S; Johnell, M; Siegbahn, A; Varenhorst, C; Wallentin, L; Winters, KJ	1
Wiviott, SD	1
Eikelboom, JW; Hirsh, J; Raju, NC	1
Ernest, CS; Rohatagi, S; Salazar, DE; Small, DS; Wallentin, L; Winters, KJ; Wrishko, RE	1
Goodsaid, FM	1
Brandt, JT; Ernest, CS; Farid, NA; Jakubowski, JA; Konkoy, CS; Li, YG; Payne, CD; Salazar, DE; Small, DS; Winters, KJ	1
Farid, NA; Hagihara, K; Ikeda, T; Ito, T; Kurihara, A; Miura, S; Nishiya, Y; Tajima, M	1
Brandt, JT; Braun, OO; Erlinge, D; Jakubowski, JA; James, S; Siegbahn, A; Sugidachi, A; Varenhorst, C; Wallentin, L; Winters, KJ	1
Cairns, JA; Eikelboom, J	1
Dachs, R; Darby-Stewart, A; Graber, MA	1
De Servi, S; Mariani, G; Mariani, M	1
Farid, NA; Hagihara, K; Ikeda, T; Kazui, M; Kurihara, A; Nishiya, Y	1
Calatzis, A	1
Kopyleva, O; Serebruany, V; Shalito, I	1
Crain, EJ; Hua, J; Rehfuss, R; Schumacher, WA; Watson, CA; Wong, PC	1
Akram, F; Akram, S; Postuła, M	1
Faxon, DP; Freedman, JE	1
Brandt, JT; Braun, OO; Erlinge, D; Jakubowski, JA; James, S; Olofsson, S; Siegbahn, A; Varenhorst, C; Wallentin, L; Winters, KJ	1
Stone, GW	3
Antman, EM; Braunwald, E; Gibson, CM; McCabe, CH; Montalescot, G; Murphy, SA; Wiviott, SD	1
Giugliano, RP; Thomas, D	1
Farid, NA; Fusegawa, K; Hagihara, K; Ikeda, T; Ikenaga, H; Kazui, M; Kurihara, A; Nanba, T; Okazaki, O; Takahashi, M	1
Sabatine, MS	1
Antonino, MJ; Gurbel, PA; Mahla, E; Tantry, US	1
Angiolillo, DJ; Capranzano, P; Ferreiro, JL	1
Butt, M; Lip, GY; Shantsila, E; Siddique, A	1
Gleason, PP; Kjesbo, NK; Schafer, JA	1
Brandt, JT; Braun, OO; Close, SL; Erlinge, D; James, S; Man, M; Siegbahn, A; Varenhorst, C; Walker, J; Wallentin, L; Winters, KJ	1
Angiolillo, DJ; Antman, EM; Braunwald, E; Downey, WE; Frelinger, AL; Jakubowski, JA; Li, Y; McCabe, CH; Michelson, AD; Murphy, SA; Qin, J; Wiviott, SD; Xenopoulos, NP	1
Marzot, F; Pengo, V	1
Cryer, B	1
Das, K; Das, P; Koshy, SK; Robinson, A	1
Antman, EM; Bonaca, MP; Bramucci, E; Braunwald, E; McCabe, CH; Morrow, DA; Murphy, SA; Nicolau, JC; Ruff, CT; Scirica, BM; White, HD; Wiviott, SD	1
Price, MJ	3
Motovska, Z; Widimsky, P	1
Floyd, J; Wolfe, S	1
Gladding, P; Webster, MW	1
Shil, AB; Strohm, MP	1
Barthélémy, O; Beygui, F; Collet, JP; Funck-Brentano, C; Hulot, JS; Montalescot, G; Pena, A; Silvain, J	1
Makarov, LM; Serebruany, VL	1
Rees, C; Spinler, SA	1
Curtiss, FR; Fairman, KA	1
Eberli, FR; Roffi, M	1
Petersen, KU	1
Alban, S; Dingermann, T	1
Alban, S	1
Breitkreutz, J	1
Kereiakes, DJ	1
Wallentin, L	1
Brandt, JT; Ernest, CS; Farid, NA; Jakubowski, JA; Li, YG; Ni, L; Payne, CD; Rohatagi, S; Small, DS; Winters, KJ	1
Duggan, ST; Keating, GM	1
Antman, EM; Braunwald, E; Finkelstein, A; Fridrich, V; McCabe, CH; Murphy, SA; O'Donoghue, M; Penny, WF; Sabatine, MS; Steg, PG; Wiviott, SD	1
Kumar, A; Roberts, DH	1
Berntsson, P; Björkman, JA; van Giezen, JJ; Zachrisson, H	1
Hayden, EC	1
Dauerman, HL	1
Antman, EM; Braunwald, E; Buros, JL; Gibson, CM; Pride, YB; Tariq, MU; Wiviott, SD; Zorkun, C	1
Farid, NA; Hagihara, K; Honda, K; Ikeda, T; Kazui, M; Kurihara, A; Okazaki, O; Yoshiike, M	1
Schömig, A	1
Kastrati, A; Sibbing, D	1
Antman, EM; Bates, ER; Braunwald, E; Close, SL; Hautvast, RW; Mega, JL; Michelson, AD; Murphy, SA; O'Donoghue, ML; Rozenman, Y; Sabatine, MS; Shen, L; Ver Lee, PN; Wiviott, SD	1
Farid, NA; Hagihara, K; Ikeda, T; Kurihara, A; Nishiya, Y; Okazaki, O; Okudaira, N	1
Collet, JP; Hulot, JS; Montalescot, G	1
Menon, V; Raymond, C	1
Oberpichler-Schwenk, H	1
Abu-Fadel, M; Norgard, NB	1
Eshaghian, S; Kaul, S; Shah, PK	1
Banach, M; Hannam, S; Kowalczyk, M; Mikhailidis, DP; Rysz, J	1
Dobesh, PP	1
Baker, WL; Reinhart, KM; White, CM	1
Farid, NA; Kurihara, A; Wrighton, SA	1
Lazar, LD; Lincoff, AM	1
del Río, A; Heras, M	1
Guerra, DR; Tcheng, JE	1
Antman, E; Arnold, SV; Braunwald, E; Cohen, DJ; Mahoney, EM; Proskorovsky, I; Wang, K; Wiviott, S	1
Jilma, B; Krumphuber, J; Siller-Matula, JM	1
Bal dit Sollier, C; Barthélémy, O; Beygui, F; Cohen, R; Collet, JP; Drouet, L; Henry, P; Lim, P; Luo, J; Marshall, D; Meuleman, C; Montalescot, G; Petitjean, H; Sideris, G	1
Solomon, S; Vacek, JL	1
Cattaneo, M; Podda, GM	1
Lip, GY; Shantsila, E; Tapp, L	1
Farid, NA; Jakubowski, JA; Kelly, R; Kothare, P; Li, YG; Natanegara, F; Ni, L; Payne, CD; Richard Lachno, D; Salazar, DE; Small, DS; Teng Loh, M; Tomlin, M; Winters, KJ; Yuen, E	1
Banning, AP; Bedogni, F; Bhindi, R; Biondi Zoccai, GG; Brambilla, N; Lanotte, S; Latini, RA; Laudisa, ML; Pizzocri, S; Testa, L; Valgimigli, M; Van Gaal, WJ	1
Islam, AM; Patel, PM	1
Fareed, J; Jeske, WP; Mousa, SA	1
Gladding, P; Webster, M; White, H	1
Guo, KW; Tan, JW	1
Aylward, PE; Behan, MW; Chew, DP	1
Jakubowski, JA; Li, YG; Luo, J; Payne, CD; Small, DS; Tomlin, ME; Winters, KJ	1
Bareiss, P; Kessler, L; Morel, O; Ohlmann, P	1
Abbate, R; Crea, F; De Servi, S; Filippi, E; Gensini, GF; Golinos, P; Savonitto, S	1
Chew, DP; Prakash, R; Wong, YW	1
Neumann, FJ	1
Amin, AP; Marso, SP	1
Duconge, J; Ruaño, G; Seip, RL	1
Dixon, SR; Grines, CL; O'Neill, WW	1
Bauters, C; Bonello, L; Delhaye, C; Lablanche, JM; Lemesle, G; Maluenda, G; Sudre, A	1
Horowitz, JD; McKinnon, RA; Sorich, MJ; Vitry, A; Ward, MB	1
Erdem, G; Flather, MD; Geisler, T	1
Bagust, A; Boland, A; Dickson, R; Dundar, Y; Fisher, M; Fleeman, N; Greenhalgh, J; Kolamunnage-Dona, R; McLeod, C; Proudlove, C; Saborido, CM	1
Cairns, JA; Eikelboom, JW; Hirsh, J; Paikin, JS	1
Armstrong, PW; Brown, E; Chin, CT; Fox, KA; Lokhnygina, Y; Marshall, DA; Ohman, EM; Petitjean, H; Prabhakaran, D; Roe, MT; White, HD	1
Boonbaichaiyapruck, S; Ge, J; Goh, YS; Hong, BK; Hou, CJ; Pinton, P; Zhu, J	1
Gratsianskiĭ, NA	1
Pakhomov, IaM	2
Antman, EM; Braunwald, E; Wiviott, SD	1
Caglayan, E; Er, F; Erdmann, E; Gassanov, N; Nia, AM	1
Aïssaoui, N; Danchin, N	1
Gurbel, PA; Mahla, E; Metzler, H; Tantry, US	1
Antman, EM; Braunwald, E; Close, SL; Mega, JL; Sabatine, MS; Shen, L; Simon, T; Walker, JR; Wiviott, SD	1
Abbate, R; Giusti, B	1
Hallström, S; Jakubowski, A; Koidl, B; Lang, P; Mächler, H; Pelzmann, B; Zorn-Pauly, K	1
Laizure, SC; Parker, RB	1
Angiolillo, DJ; Costigan, TM; Deraad, R; Effron, MB; Frelinger, AL; Gurbel, PA; Jakubowski, JA; Ojeh, CK; Saucedo, JF	1
Braber, TL; Van Der Have-Roeffel, SM; van Werkum, JW; Verheggen, PW	1
Fletcher, B; Thalinger, KK	1
Ancrenaz, V; Besson, M; Daali, Y; Dayer, P; Desmeules, J; Fontana, P; Samer, C	1
Ferrandis, R; Gómez-Luque, A; Llau, JV; Sierra, P	1
Abraham, NS; Antman, EM; Bhatt, DL; Bjorkman, DJ; Clark, CB; Furberg, CD; Hlatky, MA; Johnson, DA; Kahi, CJ; Laine, L; Mahaffey, KW; Quigley, EM; Scheiman, J; Sperling, LS; Tomaselli, GF	2
Bhavaraju, K; Gartner, TK; Georgakis, A; Jin, J; Kunapuli, SP; Nurden, A; Nurden, P; Tomiyama, Y	1
Capranzano, P; Dangas, G; Mehran, R; Stone, GW; Tamburino, C	1
De Rosa, G; Napodano, M; Padrini, R; Pengo, V; Plebani, M; Silvano, M; Zambon, CF	1
Antman, EM; Baracioli, L; Braunwald, E; Giugliano, RP; Heuer, H; Lotan, C; Merkely, B; Murphy, SA; Ruff, CT; Schersten, F; Seabro-Gomes, R; Wiviott, SD	1
Silber, S	1
Cannon, C; Croce, K; Kirshenbaum, J; Manica, A; Marchini, J; Morrow, D; Resnic, F	1
Armani, AM	1
Angiolillo, DJ; Tello-Montoliu, A; Tomasello, SD	1
Minarelli, M; Valgimigli, M	1
Frey, N; Ivandic, B	1
Ağırbaşlı, M; Cinçin, A; Güvenç, H	1
Endres, HG; Engelhardt, A; Kaiser, AF; Krüger, JC; Kusber, A; Lask, S; Mügge, A; Neubauer, H; Pepinghege, F	1
Angiolillo, DJ; Badimon, JJ; Baker, BA; Effron, MB; Frelinger, AL; Jakubowski, JA; Michelson, AD; Ojeh, CK; Saucedo, JF; Zhu, B	1
Cohen Arazi, H; Di Girolamo, G; Giorgi, MA; Gonzalez, CD	1
Baker, BA; Effron, MB; Jakubowski, JA; Kulkarni, MP; Li, YG; Luo, J; Miller, DL; Small, DS; Winters, KJ; Zhu, B	1
Engelen, S; Sinnaeve, P; Van Damme, H; Verhamme, P	1
Hamm, CW; Rassaf, T	1
Achar, S	1
Campo, G; Ferrari, R; Fileti, L; Marchesini, J; Valgimigli, M	1
Smetana, GW; Srour, JF	1
Lange, CG	1
Arntz, HR; Boudriot, E; Garlichs, C; Helms, TM; Hoffmann, S; Ince, H; Klingenheben, T; Silber, S; Steiger, H; Weil, J; Zugck, C	1
Scharf, RE	1
Baty, SR; Griffith, CB; Phillippe, HM	1
Storey, RF	1
Briongos Figuero, S; de Juan-Bagudá, J; Martí-Sánchez, D; Salido-Tahoces, L	1
Alexopoulos, D; Athanassiadou, A; Davlouros, P; Dimitropoulos, G; Hahalis, G; Kassimis, G; Stavrou, EF; Xanthopoulou, I	1
Bellemain, A; Collet, JP; Ecollan, P; Montalescot, G; Silvain, J	1
Behr, T; Behr, W; Kuch, B; von Scheidt, W	1
Castriota, F; De Luca, G; De Servi, S; Kozinski, M; Kubica, J; Navarese, EP; Schaffer, A; Suriano, P; Verdoia, M	1
Cattaneo, GJ; Cattaneo, M; Podda, GM	1
Easton, JD	1
Antman, EM; Braunwald, E; Contant, CF; Dalby, AJ; Giugliano, RP; Guo, J; Hochholzer, W; Montalescot, G; Wiviott, SD	1
Moliterno, DJ; Rajan, L	1
Eikelboom, JW; Fitchett, DH; Goodman, SG; Mehta, SR; Quinlan, DJ; Théroux, P; Welsh, RC	1
Martin, MT; Nutescu, EA; Spinler, SA	1
Kanadiya, MK; Koshal, VB; Singhal, S	1
Ferro, A; Passacquale, G	1
Close, SL; Farid, NA; Ho, M; Jakubowski, JA; Kelly, RP; Natanegara, F; Shen, L; Small, DS; Walker, JR; Winters, KJ	1
Antman, EM; Braunwald, E; Costigan, TM; Frelinger, AL; Jakubowski, JA; McCabe, CH; Michelson, AD; Miller, DL; Neumann, FJ; Trenk, D; Wiviott, SD	1
Carballo, D; Carballo, S; Keller, PF; Roffi, M	1
Flaherty, MP; Johnston, PV; Rade, JJ	1
Byrne, RA; Hausleiter, J; Laugwitz, KL; Orban, M; Sibbing, D	1
Alexopoulos, D	1
Alber, HF; Frick, M; Huber, K; Pachinger, O	1
Bonello, L; de Labriolle, A; Doazan, JP; Lemesle, G	1
Anderson, RA; Bundhoo, SS; Dada, J; Halcox, JP; Harris, R; James, PE; Lang, D; Sagan, E	1
Abell, LM; Liu, EC	1
Bonafede, M; Deitelzweig, SB; Gdovin Bergeson, J; Graham, J; Jing, Y; Liffmann, D; Makenbaeva, D	1
Bernlochner, I; Contant, CF; Guo, J; Hochholzer, W; Kastrati, A; Mega, JL; Morath, T; Neumann, FJ; O'Donoghue, ML; Sabatine, MS; Schömig, A; Sibbing, D; Stratz, C; Trenk, D; Valina, CM; Wiviott, SD	1
Beddingfield, R; Held-Godgluck, BM; Peppard, SR	1
D'Urbano, M; De Servi, S; Navarese, EP; Savonitto, S	1
Rayoo, R; Sharma, N; van Gaal, WJ	1
Alexopoulos, D; Davlouros, P; Hahalis, G; Mavronasiou, E; Panagiotou, A; Plakomyti, TE; Xanthopoulou, I	1
Alexopoulos, D; Davlouros, P; Fourtounas, C; Goumenos, D; Kassimis, G; Komninakis, D; Panagiotou, A; Xanthopoulou, I	1
Danenberg, HD; Raccah, BH; Shalit, M	1
Angiolillo, DJ; Calvi, V; Capodanno, D; Capranzano, P; D'Urso, L; Miccichè, E; Tamburino, C	1
Cayla, G; Collet, JP; Montalescot, G; O'Connor, SA; Silvain, J	2
Bae, JP; Cohen, DJ; Graham, JB; Magnuson, EA; Mauskopf, JA; Meadows, ES; Ramaswamy, K; Zagar, AJ	1
Barthélémy, O; Bellemain-Appaix, A; Beygui, F; Cayla, G; Collet, JP; Finzi, J; Hulot, JS; Kerneis, M; Montalescot, G; O'Connor, SA; Silvain, J	1
Alexopoulos, D; Plakomyti, TE; Xanthopoulou, I	1
Basra, SS; Lakkis, NM; Tsai, P	1
Barakoti, M; Neupane, P; Pant, S; Ramesh, KC	1
Chopra, P; Klaustermeyer, WB; Verma, P	1
Ikeda, Y; Isshiki, T; Kimura, T; Ogawa, H; Yokoi, H	1
Collet, JP; De Luca, L; Wouter Jukema, J	1
Damman, P; de Winter, RJ; James, SK; Kuijt, WJ; Woudstra, P	1
Becker, RC; Cutlip, DE; Dauerman, HL; French, PA; Granada, JF; Price, MJ; Smyth, SS; Steinhubl, SR	1
Braunwald, E	1
Abraham, T; Balmir, E; Oh, EY; Rapp, JH; Saad, N; Vastey, FL	1
Janknegt, R; Ruiters, L; Ten Cate, H	1
Davies, JE; Francis, DP; Nijjer, SS	1
Castriota, F; Grzesk, E; Grzesk, G; Kozinski, M; Krzyzanowski, M; Kubica, A; Kubica, J; Navarese, EP; Siller-Matula, JM	1
Gurbel, PA; Jeong, YH; Ohman, EM; Tantry, US	1
Kern, MJ	1
Hsu, PI	1
Mutnick, JL	1
Mackay, SM; Tcheng, JE	1
Contractor, H; Ruparelia, N	1
Baker, BA; Bernlochner, I; Brown, PB; Gupta, N; Jakubowski, JA; Kastrati, A; Morath, T; Schömig, A; Sibbing, D; Winters, KJ; Zhou, C	1
Carbonell-Porras, A; Fernández-Ruiz, M; García-Reyne, A; López-Medrano, F	1
Coulter, CJ; Montandon, SV	1
Grześk, G; Koziński, M; Kubica, J	1
Grajek, S	1
Gong, Y; Jiao, B; Lv, F; Qi, X; Shan, J; Sun, H; Yuan, F; Zhang, B; Zheng, W; Zhu, Y	1
Askari, AT; Stephens, JC	1
Bristot, L; Campo, G; Ferrari, R; Gambetti, S; Monti, M; Parrinello, G; Tebaldi, M; Valgimigli, M	1
Bradley, SM; Guzauskas, GF; Hughes, DA; Veenstra, DL	1
Cavallari, LH; Schumock, GT	1
Beitelshees, AL; Daniel Mullins, C; Onukwugha, E; Reese, ES	1
Dick, A; Druce, I; Froeschl, M; Glover, C; Gollob, MH; Goncalves, S; Labinaz, M; Le May, MR; Marquis, JF; O'Brien, E; Roberts, JD; So, DY; Stewart, A; Wells, GA	1
Harding, SA; Johnston, LR; La Flamme, AC; Larsen, PD; Michel, JM; Simmonds, MB	1
Goss, FR; Pauker, SG	1
Angiolillo, DJ; Gawaz, M; Jakubowski, JA; Kastrati, A; Müller, U; Neumann, FJ; Richardt, G; Stone, GW; Trenk, D	1
Ferro, A; Floyd, CN; Passacquale, G	1
Angiolillo, DJ; Azmoon, S	1
Lyseng-Williamson, KA	1
Mustonen, P; Puurunen, M	1
Halperin, JL; Varughese, CJ	1
Bessereau, J; Bonello, L; Camoin-Jau, L; Paganelli, F; Uhry, S	1
Chen, CH; Lin, CJ; Uang, YS; Yang, JC	1
Chen, L; Coyle, D; Moertl, D; Steiner, S; Wells, GA	1
Goodnough, LT; Lenarz, LA; Levy, JH; Poston, RS; Short, MA; Smith, PK; Weerakkody, GJ	2
Christ, G; Dechant, C; Delle-Karth, G; Francesconi, M; Gouya, G; Jilma, B; Maurer, G; Podczeck-Schweighofer, A; Ruzicka, K; Siller-Matula, JM	1
Hausleiter, J; Joner, M; Kastrati, A; Massberg, S; Okrojek, R; Orban, M; Riegger, J; Sibbing, D; Tada, T	1
Gupta, A; Hirst, J; McKay, RG; Rai, M; Ruaño, G; Seip, RL; Thompson, PD	1
Freynhofer, MK; Höchtl, T; Huber, K; Mahla, E; Prüller, F	1
Heptinstall, S; Joshi, R; Wijeyeratne, YD	1
Angiolillo, DJ; Baker, BA; Heiselman, DE; Jakubowski, JA; Li, W; Logan, DK; Price, MJ; Walder, JS; Winters, KJ	1
Ahmad, S; Storey, RF	1
Bessereau, J; Bonello, L; Camoin-Jau, L; Laine, M; Paganelli, F; Sébastien, A	1
Bhatt, DL; Kar, S	1
Barn, K; Steinhubl, SR	1
Grove, EL; Hvas, AM; Kristensen, SD	1
Carrié, D; Garcia, C; Lhermusier, T; Mejean, S; Sié, P; Voisin, S	1
Budaj, A; Gurbel, PA; Tantry, US	1
Gurbel, PA; Jeong, YH; Tantry, US	1
Alexopoulos, D; Damelou, A; Davlouros, P; Galati, A; Hahalis, G; Kassimis, G; Makris, G; Mavronasiou, E; Theodoropoulos, KC; Tsigkas, G; Xanthopoulou, I	1
Alexander, KP; Foody, JM; Funk, M; Granger, CB; Li, L; Lopes, RD; Peterson, ED; Wang, TY	1
Limper, U; Lynch, J	1
Chan, KH; Chan, MY; Lee, CH; Li, Y; Low, A; Phua, QH; Richards, MA; Roe, MT; Sia, W; Sim, TB; Tai, BC; Tan, HC; Teo, SG; Yeo, TC	1
Huber, K	1
Harrison, P	1
Bernlochner, I; Braun, S; Kastrati, A; Koch, W; Mayer, K; Morath, T; Schömig, A; Schulz, S; Sibbing, D	1
Bernlochner, I; Sibbing, D	1
Ardissino, D; Armstrong, PW; Aylward, PE; Bhatt, DL; Boden, WE; Brown, EB; Cinteză, M; Clemmensen, P; Corbalan, R; Cornel, JH; Dalby, AJ; Fox, KA; Gasparovic, V; Goodman, SG; Gottlieb, S; Goudev, AR; Gurbel, PA; Hamm, C; Hochman, JS; Huber, K; Leiva-Pons, JL; Lokhnygina, Y; Martinez, F; McGuire, DK; McLendon, RC; Merkely, B; Nicolau, JC; Ohman, EM; Oto, A; Parkhomenko, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; Topacio, GO; Tseng, CD; White, HD; Winters, KJ	1
Alexopoulos, D; Athanassiadou, A; Damelou, A; Davlouros, P; Hahalis, G; Kassimis, G; Stavrou, EF; Theodoropoulos, KC; Tsigkas, G; Xanthopoulou, I	1
Chan, MY; Li, Y	1
Brown, PM; Gladding, P; Panattoni, L; Te Ao, B; Webster, M	1
Kastrati, A	1
Badr Eslam, R; Calatzis, A; Gremmel, T; Koppensteiner, R; Lang, IM; Panzer, S	1
Benedetti, G; Biondi-Zoccai, G; Calcagno, S; Canali, E; Di Roma, A; Fedele, F; Guadagni, F; Lucisano, L; Mancone, M; Palmirotta, R; Pennacchi, M; Sardella, G; Stio, RE	1
Badimon, JJ; Becker, EM; Bütehorn, U; Kast, R; Klipp, A; Laux, V; Lücker, C; Perzborn, E	1
Angiolillo, DJ; Bergmeijer, T; Brown, PB; Erlinge, D; Foley, D; Jakubowski, JA; James, S; Luo, J; Moser, B; Small, DS; Ten Berg, J; Wagner, H; Winters, KJ; Zhou, C	1
Alessi, MC; Beguin, S; Bonnet, JL; Cuisset, T; Dubois, N; Dutour, A; Gaborit, B; Loosveld, M; Loundou, AD; Morange, PE; Moro, PJ; Quilici, J	1
Arthur, AS; Hoit, DA; Jones, GM; Twilla, JD	2
Choi, KN; Chung, SR; Do, U; Jang, JS; Jin, HY; Kim, DK; Kim, DS; Kim, HJ; Seo, JS; Yang, TH	1
Armstrong, JM; Bandarenko, N; Barnato, SE; Bennett, CL; Carey, PM; Chen, F; Chen, H; Clark, WF; Cursio, JF; Danielson, C; Dunn, BL; Fujimura, Y; Jacob, S; Kiss, JE; Kwaan, HC; Matsumoto, M; McKoy, JM; Ortel, TL; Pandey, DK; Qureshi, ZP; Raife, TJ; Raisch, DW; Rock, G; Sarode, R; Weiss, I; Winters, JL; Zheng, XL	1
Armstrong, PW; Brown, E; Chan, MY; Cornel, JH; Erlinge, D; Fox, KA; Goodman, SG; Gurbel, PA; Huber, K; Jakubowski, JA; Neely, B; Neely, M; Ohman, EM; Prabhakaran, D; Roe, MT; Tantry, US; White, HD; Zhou, C	1
Abtan, J; Aubry, P; Barthélémy, O; Belle, L; Beygui, F; Boueri, Z; Carrié, D; Cayla, G; Collet, JP; Cuisset, T; Elhadad, S; Henry, P; Kerneis, M; Monségu, J; Montalescot, G; Motreff, P; O'Connor, SA; Pouillot, C; Rangé, G; Rousseau, H; Sabouret, P; Saint-Etienne, C; Silvain, J; Van Belle, E; Vicaut, E	1
Berger, JS; Hochman, JS; Ladapo, JA; Lala, A; Scott Braithwaite, R; Sharma, G	1
Baeriswyl, G; Cook, S; Goy, JJ; Lehmann, S; Lehner, C; Oberhänsli, M; Puricel, S; Stauffer, JC; Togni, M	1
Bolognese, L; De Servi, S	1
Chen, X; Fan, Z; Li, N; Liu, Q; Lu, Y; Qiu, Z; Song, L; Tian, F; Wang, X	1
Aradi, D; Komócsi, A; Serebruany, VL; Vorobcsuk, A	1
Cohen, DJ; Jones, PG; Li, Y; Salisbury, AC; Spertus, JA; Wang, K	1
Chatterjee, S; Frankel, R; Ghose, A; Guha, G; Mukherjee, D; Sharma, A	1
Amann, M; Hochholzer, W; Leggewie, S; Neumann, FJ; Nührenberg, TG; Ristau, I; Stratz, C; Trenk, D; Valina, CM	1
Angiolillo, DJ; Costigan, TM; DeRaad, R; Duvvuru, S; Effron, MB; Frelinger, AL; Gurbel, PA; Jakubowski, JA; Ojeh, CK; Saucedo, JF	1
Alexopoulos, D; Damelou, A; Davlouros, P; Hahalis, G; Mavronasiou, E; Plakomyti, TE; Theodoropoulos, KC; Xanthopoulou, I	1
Kiss, RG	1
Chen, F; Kent, KM; Kitabata, H; Loh, JP; Pendyala, LK; Pichard, AD; Satler, LF; Suddath, WO; Torguson, R; Waksman, R	1
Benjamin, MM; Donsky, MS; Filardo, G; Schussler, JM	1
Fareed, J; Jeske, W; Thethi, I	1
Daly, RL; Dhutia, AJ; Ecob, R; Howgego, KE; Judge, HM; Mehra, S; Morton, AC; Storey, RF; Sumaya, W	1
Goto, S; Tomiya, A	1
Eslam, RB; Gremmel, T; Koppensteiner, R; Lang, IM; Panzer, S	1
Maddox, TM	1
Bernlochner, I; Braun, S; Kastrati, A; Mayer, K; Morath, T; Orban, M; Schömig, A; Schulz, S; Sibbing, D	1
Bakhai, A; Barrett, A; Davies, A; Graham-Clarke, P; Schmitt, C; Sculpher, M	1
Alessi, MC; Beguin, S; Bonnet, JL; Camoin, L; Cohen, W; Cuisset, T; Gaborit, B; Grosdidier, C; Lambert, M; Loosveld, M; Morange, PE; Moro, PJ; Pankert, M; Quilici, J; Saut, N	1
Jung, DK; Kim, MH; Zhang, HZ	1
Can, MM; Dinicolantonio, JJ; Goto, S; Serebruany, VL	1
Clemmensen, P; Dridi, NP; Holmvang, L	1
Aronow, WS	2
Agewall, S; Andreotti, F; Atar, D; Cattaneo, M; Collet, JP; Grove, EL; Huber, K; Husted, S; Kjeldsen, K; Lip, GY; Morais, J; Pathak, A; Rosano, G; Storey, RF; Verheugt, FW; Wassmann, S	1
Abtan, J; Barthélémy, O; Beygui, F; Brugier, D; Cayla, G; Collet, JP; Kerneis, M; Martin, R; Montalescot, G; O'Connor, SA; Silvain, J; Vignalou, JB	1
Angiolillo, DJ; Rollini, F	1
Kim, MH; Lee, DH; Lee, MS; Park, JS; Park, K; Park, TH; Seo, JM; Zhang, HZ	1
Felix-Getzik, E; Sylvia, LM	1
Alexopoulos, D; Davlouros, P; Mavronasiou, E; Siapika, A; Stavrou, K; Tsoni, E; Xanthopoulou, I	1
Kastrati, A; Martischnig, A; Mayer, K; Mehilli, J; Sarafoff, N; Sibbing, D; Wealer, J	1
Bonello, L; Frere, C; Laine, M; Paganelli, F; Toesca, R	1
Bertho, G; Dansette, PM; Hessani, A; Levent, D; Mansuy, D	1
Gurbel, PA; Jeong, YH; Kubica, J; Navarese, EP; Tantry, US	1
Stiefelhagen, P	1
Wang, H; Wang, WE; Wang, X; Zeng, C	1
Erlinge, D; Larsson, J; Ohman, J; Salmi, H; Torngren, K	1
Angiolillo, DJ; Bailey, WL; Baker, BA; Bliden, KP; Gurbel, PA; Jakubowski, JA; Jeong, YH; Kereiakes, DJ; Lasseter, KC; Logan, DK; Maa, JF; Nolin, TD; Ojeh, CK; Tantry, US; White, A	1
Gremmel, T; Kopp, CW; Koppensteiner, R; Panzer, S; Seidinger, D; Steiner, S	1
Franken, CC; Kaiser, AF; Krüger, JC; Mügge, A; Neubauer, H; Overbeck, K	1
Coleman, CI; Limone, BL	1
Eikelboom, J; Fitchett, D; Mazer, CD; Verma, S	1
Oprea, AD; Popescu, WM	1
Enar, R	1
Göddertz, R	1
de Lemos, JA; Diercks, DB; Hollander, JE; Holmes, DN; Kontos, MC; Mumma, BE; Saucedo, JF; Wiviott, S	1
Baron, TH; Kamath, PS; McBane, RD	1
DiNicolantonio, JJ; Serebruany, VL	1
Huber, K; Lip, GY	1
Angiolillo, DJ; Brown, PB; Erlinge, D; Foley, DP; Gurbel, PA; Jakubowski, JA; James, S; Lindahl, TL; Luo, J; Moser, BA; Small, DS; Svensson, P; Ten Berg, JM; Wagner, H; Winters, KJ; Zhou, C	1
Bonello, L; Frère, C; Laine, M; Paganelli, F	1
Apostolakis, S; Lip, GY; Shantsila, E	1
Conde, D; Elissamburu, P; Lalor, N; Rodriguez, L; Trivi, M	2
Christ, G; Francesconi, M; Grohs, K; Hafner, T; Podczeck-Schweighofer, A; Siller-Matula, JM; Wilhelm, E	1
Ardissino, D; Armstrong, PW; Aylward, PE; Bassand, JP; Boden, WE; Dalby, AJ; Fox, KA; Goodman, SG; Gottlieb, S; Hochman, JS; Martinez, F; McGuire, DK; Ohman, EM; Prabhakaran, D; Roe, MT; Stevens, SR; White, HD; Winters, KJ	1
Can, MM; Dinicolantonio, JJ; Kuliczkowski, W; Pershukov, IV; Serebruany, VL	1
Bray, PF; DeLa Cadena, RA; Garcia, AE; Kunapuli, SP; Liverani, E; Rico, MC	1
Aradi, D; Baumstarck, K; Bessereau, J; Bonello, L; Camilleri, E; Camoin-Jau, L; Dignat-George, F; Fernandez, J; Laine, M; Maillard, L; Paganelli, F; Peyrol, M; Piot, C; Roubille, F	1
Alessi, MC; Beguin, S; Bonnet, G; Bonnet, JL; Cuisset, T; Deharo, P; Grosdidier, C; Morange, P; Pankert, M; Pons, C; Quilici, J	1
Franklin, JM; Glynn, RJ; Patrick, AR; Schneeweiss, S; Weinstein, MC	1
Abtan, J; Barthélémy, O; Beygui, F; Brugier, D; Collet, JP; Kerneis, M; Montalescot, G; O'Connor, SA; Silvain, J; Vignalou, JB	1
Dinicolantonio, JJ; Norgard, NB	1
Acosta, J; Benezet, J; Cubero Gómez, JM; Díaz DE LA Llera, LS; Fernández-Cisnal, A; Parejo, J; Rangel, D; Zafra, F	1
Feldman, DN; Swaminathan, RV	1
Armstrong, PW; Bhatt, DL; Boden, WE; Clemmensen, P; Fox, KA; Hafley, G; Hamm, C; Leiva-Pons, J; Lokhnygina, Y; Menozzi, A; Nicolau, JC; Ohman, EM; Oto, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; White, HD; Widimsky, P; Winters, KJ; Wiviott, SD	1
Alessi, MC; Beguin, S; Bonnet, JL; Camoin, L; Cuisset, T; Grosdidier, C; Lambert, M; Loosveld, M; Loundou, AD; Morange, PE; Pankert, M; Quilici, J	1
Gross, L; Massberg, S; Orban, M; Sibbing, D	1
Beigel, R; Elian, D; Fefer, P; Fink, N; Guetta, V; Hod, H; Matetzky, S; Novikov, I; Rosenberg, N; Segev, A	1
Aylward, PE; Sinhal, AR	1
Alexopoulos, D; Angelidis, C; Deftereos, S; Goudevenos, JA; Hahalis, G; Hamilos, M; Kanakakis, I; Ntalas, IV; Parissis, H; Petousis, S; Sitafidis, G; Stefanadis, C; Vavuranakis, M; Xanthopoulou, I	1
Ackman, ML; Bauer, RD; Bell, AD; Cartier, R; Chan, WS; Douketis, J; Mehta, SR; Roussin, A; Schnell, G; Tanguay, JF; Verma, S; Wong, G	1
Moertl, D; Steiner, S	1
Angiolillo, DJ; Braun, OÖ; Costigan, TM; Duvvuru, S; Effron, MB; Ferreiro, JL; Jakubowski, JA; Kleiman, NS; Saucedo, JF; Sundseth, S; Varenhorst, C; Walker, JR; Winters, KJ	1
Grove, EL; Würtz, M	1
Chua, D; Nishi, C	1
Chen, X; Gao, W; Jing, J; Li, N; Lu, Y; Parekha, HS; Qiu, Z; Ren, S; Song, L; Tian, F; Wang, X	1
He, B; Kun, L; Liu, X; Wu, B	1
Abbate, R; Antoniucci, D; Carrabba, N; Gensini, GF; Marcucci, R; Migliorini, A; Parodi, G; Valenti, R	1
Antman, EM; Braunwald, E; Cannon, CP; Giugliano, RP; Mogabgab, O; Sabatine, MS; Sloan, S; Wiviott, SD	1
Angiolillo, DJ; Cardillo, TE; Diodati, JG; Effron, MB; Fisher, HN; French, JK; Fung, AY; Henneges, C; Saucedo, JF	1
Curkovic, I; Egbring, M; Kullak-Ublick, GA	1
Dugdale, M; Fabian, TC; Gordon, JL; Lee, MD	1
Acharji, S; Kaluski, E; Lakshmanadoss, U; Rudzinski, W; Stapleton, DD	1
Adsett, G; Jayasinghe, R; Markham, R	1
Becker, RC; Breithardt, G; Califf, RM; Fox, KA; Goodman, SG; Hacke, W; Halperin, JL; Hankey, GJ; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Stevens, SR; White, HD	1
Antman, EM; Braunwald, E; Cannon, CP; Kohli, P; Murphy, SA; Udell, JA; Wiviott, SD	1
Angiolillo, DJ; Bass, TA; Darlington, A; Desai, B; Ferreiro, JL; Guzman, LA; Patel, R; Rollini, F; Tello-Montoliu, A; Ueno, M	1
Damman, P; Eriksson, P; Erlinge, D; James, SK; Koul, S; Lagerqvist, B; Varenhorst, C	1
Bode, C; Diehl, P; Moser, M; Olivier, CB; Schnabel, K; Weik, P; Zhou, Q	1
Alessi, MC; Bonnet, G; Bonnet, JL; Cuisset, T; Deharo, P; Dutour, A; Gaborit, B; Lambert, M; Loundou, AD; Morange, PE; Pankert, M; Quilici, J; Valéro, R; Verdier, V	1
Brennan, T; Canestaro, WJ; Chaplin, D; Choudhry, NK; Desai, NR; Kyrychenko, P; Martell, LA; Matlin, OS	1
Verheugt, FW	1
Antman, EM; Bates, ER; Mega, JL; Murphy, SA; O'Donoghue, ML; Ojeifo, O; Sabatine, MS; Udell, JA; Wiviott, SD	1
Clemmensen, P; Dridi, NP; Engstrøm, T; Helqvist, S; Holmvang, L; Johansson, PI; Jørgensen, E; Kelbæk, H; Pedersen, F; Qayyum, A; Radu, MD; Saunamäki, K; Stissing, T	1
Dhillon, K; Dovlatova, N; Fox, SC; Glenn, JR; Heptinstall, S; White, AE	1
Alexopoulos, D; Angelidis, C; Davlouros, P; Deftereos, S; Goudevenos, J; Hamilos, M; Kanakakis, I; Parissis, H; Petousis, S; Sitafidis, G; Stakos, D; Stefanadis, C; Vavouranakis, M; Xanthopoulou, I	1
Arrich, J; Gouya, G; Gurbel, PA; Huber, K; Pirker-Kees, A; Siller-Matula, JM; Verheugt, FW; Wolzt, M	1
Angiolillo, DJ; Baker, BA; Heiselman, DE; Jakubowski, JA; Li, W; Price, MJ	1
Balasubramaniam, K; Koshy, A; Noman, A; Zaman, AG	1
Arntz, HR; Boudriot, E; Garlichs, C; Helms, TM; Hoffmann, S; Ince, H; Klingenheben, T; Schäfer, A; Silber, S; Weil, J; Zugck, C	1
Ay, C; Badr Eslam, R; Eichelberger, B; Gremmel, T; Lang, IM; Panzer, S; Posch, F	1
Alexander, T; Babu, PR; Dani, S; Dasbiswas, A; Hiremath, S; Nayak, R; Patel, T; Pathak, K; Prakash, VS; Rao, MS; Singh, DP; Srivastava, A; Tyagi, S; Vijayvergiya, R; Yadav, MK	1
Hirschl, MM	1
Aradi, D; Faluközy, J; Horváth, IG; Komócsi, A; Kónyi, A; Magyari, B; Pintér, T; Tornyos, A; Veress, G; Vorobcsuk, A	1
Gupta, K; Singh, D; Vacek, JL	1
Bohn, RL; Choudhry, NK; Daniel, GW; Gagne, JJ; Liu, J; Patrick, AR; Rassen, JA; Schneeweiss, S; Sridhar, G	1
Gnall, EM; Ice, DS; Kowey, PR; Shapiro, TA	1
Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ	1
Bailey, WL; Baker, BA; Bliden, KP; Gurbel, PA; Tantry, US	1
Coons, JC; Harris, J; Schwier, N; Seybert, AL	1
Christoph, M; Ibrahim, K; Jellinghaus, S; Kolschmann, S; Mues, C; Pfluecke, C; Quick, S; Schmeinck, S; Schmieder, K; Schoener, L; Steiding, K; Strasser, RH; Wunderlich, C	1
Duraj, L; Fedor, M; Fedorová, J; Galajda, P; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Šimonová, R; Staško, J	1
Sabouret, P; Taiel-Sartral, M	1
Brener, SJ; El-Omar, M; Gibson, CM; Maehara, A; Mehran, R; Oldroyd, KG; Stone, GW; Witzenbichler, B; Xu, K	1
Braun, D; Gershlick, AH; Hauschke, D; Ibrahim, T; Kastrati, A; Laugwitz, KL; Mayer, K; Mehilli, J; Mehran, R; Morath, T; Neudecker, J; Richardt, G; Schulz, S; Schunkert, H; Tölg, R	1
Hartung, P; Hill, K; Schaefer, M; Schulze, A	1
Delzor, F; Nanau, RM; Neuman, MG	1
Antoniucci, D; De Luca, G; Marino, P; Parodi, G; Schaffer, A; Suryapranata, H; Verdoia, M	1
Abbate, R; Antoniucci, D; Bellandi, B; Carrabba, N; Comito, V; De Luca, G; Gensini, GF; Marcucci, R; Migliorini, A; Parodi, G; Ramazzotti, RN; Valenti, R	1
Caldeira, D; Ferreira, JJ; Pinto, FJ	1
Bouatou, Y; Gabrielli, A; Saudan, P	1
Angiolillo, DJ; Cardillo, TE; Diodati, JG; Duvvuru, S; Effron, MB; Fisher, HN; Henneges, C; Jakubowski, JA; Lipkin, FR; Saucedo, JF; Sundseth, SS; Walker, JR	1
Bernlochner, I; Braun, S; Hausleiter, J; Kastrati, A; Laugwitz, KL; Massberg, S; Mayer, K; Morath, T; Schulz, S; Schunkert, H; Sibbing, D	1
Boothroyd, DB; Dudley, RA; Garber, AM; Hlatky, MA; Kazi, DS; Mell, MW; Moshkevich, S; Owens, DK; Rhee, C; Shah, RU	1
Taylor, J	1
Delemos, J; Peng, SA; Peterson, ED; Roe, MT; Sherwood, MW; Wang, TY; Wiviott, SD	1
Al-Attar, N; Amour, J; Ascione, R; Collet, JP; Falk, V; Huber, K; Leite-Moreira, AF; Sousa-Uva, M; Storey, R; Taggart, D	1
Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H	1
Adamski, P; Fabiszak, T; Grześk, G; Koziński, M; Kubica, J; Navarese, EP; Ostrowska, M; Paciorek, P	1
Gislason, G; Sørensen, R	1
Elosua, R; Marrugat, J; Vila, J	1
Fortmann, SD; Serebruany, VL	1
Abdel-Wahab, M; Anette Fiedler, K; Gershlick, AH; Hoppmann, P; Ibrahim, T; Kastrati, A; Kufner, S; Laugwitz, KL; Mehilli, J; Mehran, R; Morath, T; Neudecker, J; Richardt, G; Schneider, S; Schulz, S; Schunkert, H; Tölg, R	1
Massberg, S; Sibbing, D	1
Harrington, RA; Himmelmann, A; Steg, PG; Storey, RF; Wallentin, L	1
De Servi, S; Goedicke, J; Schirmer, A; Widimsky, P	1
Bataille, V; Carrié, D; Garcia, C; Lhermusier, T; Lipinski, MJ; Mejean, S; Murat, G; Sié, P; Voisin, S	1
Bolliger, D; Drews, S; Eckstein, F; Grapow, M; Kaiser, C; Matt, P; Reuthebuch, O	1
Maloof, JA; Williams, MF	1
Antman, EM; Braunwald, E; Montalescot, G; Murphy, SA; Udell, JA; Wiviott, SD	1
Roe, MT; Sherwood, MW	1
Chan, NC; Eikelboom, JW; Ginsberg, JS; Hirsh, J; Lauw, MN; Vanassche, T; Weitz, JI	1
Armstrong, PW; Clemmensen, P; Cornel, JH; Fox, KA; Gurbel, PA; Neely, B; Ohman, EM; Prabhakaran, D; Roe, MT; Sritara, P; White, HD; Zamoryakhin, D	1
Angiolillo, DJ; Bergmeijer, TO; Brown, PB; Duvvuru, S; Erlinge, D; Gurbel, PA; Jakubowski, JA; James, S; Lindahl, TL; Moser, BA; Small, D; Sundseth, S; Svensson, P; Tantry, US; ten Berg, JM; Walker, JR; Winters, KJ	1
Abtan, J; Anzaha, G; Barthélémy, O; Beygui, F; Brugier, D; Cayla, G; Charland, SL; Collet, JP; Galier, S; Gallois, V; Hulot, JS; Kerneis, M; Montalescot, G; O'Connor, SA; Silvain, J; Stanek, EJ	1
Costigan, T; Iqbal, K; Lopez-Sendon, J; Ramos, Y; Widimsky, P; Wilcox, R	1
Bae, JP; Effron, MB; Ernst, FR; Faries, DE; Lieu, HD; Lipkin, C; Moretz, C; Zhao, Z	1
Alexander, KP; Bagai, A; Bhatt, DL; Cheema, AN; Curtis, JP; Granger, CB; Gurm, HS; McNamara, RL; Peterson, ED; Roe, MT; Saucedo, JF; Shah, B; Wang, TY; Wang, Y	1
Abendschein, D; Broekman, MJ; Chen, R; Drosopoulos, JH; Jeong, SS; Marcus, AJ; Moeckel, D; Nguyen, A; Robson, SC; Sun, X	1
Christ, G; Dechant, C; Delle-Karth, G; Francesconi, M; Grohs, K; Gruber, C; Jilma, B; Podczeck-Schweighofer, A; Siller-Matula, JM	1
Bernlochner, I; Braun, S; Hadamitzky, M; Hausleiter, J; Hoppmann, P; Kastrati, A; Laugwitz, KL; Massberg, S; Mayer, K; Mehilli, J; Morath, T; Orban, M; Schulz, S; Schunkert, H; Sibbing, D; Tiroch, K	1
Fauchère, I; Schreiber, P; Wyss, C	1
Crivera, C; Dea, K; Fields, LE; Germain, G; Laliberté, F; Lefebvre, P; Lynch, SM; Ma, YW; Olson, WH; Schein, JR	1
Vengoechea, F	1
Ikeda, Y; Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H	1
Christ, G; Dechant, C; Francesconi, M; Grohs, K; Podczeck-Schweighofer, A; Siller-Matula, JM	1
Chieffo, A; Colombo, A	1
Braunwald, E; Cohen, DJ; Cutlip, DE; Dauerman, HL; Driscoll-Shempp, P; Garratt, KN; Hermiller, J; Holmes, DR; Kandzari, DE; Kereiakes, DJ; Krucoff, MW; Lee, DP; Massaro, JM; Mauri, L; Normand, SL; Pow, TK; Rinaldi, MJ; Simon, DI; Steg, PG; Ver Lee, P; Wiviott, SD; Yeh, RW	1
Bae, JP; Candrilli, SD; Drenning, D; Fortenberry, J; Jakubowski, JA; Meyers, JL	1
Andell, P; Björnsson, S; Erlinge, D; Götberg, M; Harnek, J; Koul, S; Martinsson, A; Norström, E; Scherstén, F; Smith, JG	1
Anderson, JL; Goto, S; Huo, Y; Jeong, YH; Levine, GN; Mega, JL; Smith, SC; Taubert, K	1
Arntz, HR; Diller, F; Mark, B; Mochmann, HC; Montalescot, G; Thiele, H; Zahn, R; Zeymer, U	1
Lhermusier, T; Waksman, R	1
Assinger, A; Kral, JB; Scharbert, G; Schrottmaier, WC; Weber, T; Wetzel, L	1
Jiang, M; You, JH	1
Bultas, J	1
Baker, N; Bliden, KP; Chen, F; Escarcega, RO; Gurbel, PA; Lhermusier, T; Lipinski, MJ; Magalhaes, MA; Minha, S; Ota, H; Pendyala, L; Tantry, US; Tian, W; Torguson, R; Waksman, R	1
Calıskan, A; Demirtas, S; Guclu, O; Kaplan, I; Karahan, O; Tezcan, O; Yavuz, C; Yazıcı, S	1
Amsallem, M; Bal dit Sollier, C; Dillinger, JG; Drouet, L; Henry, P; Manzo-Silberman, S; Sideris, G; Voicu, S	1
Steg, PG; Wiviott, SD	1
Auer, R; Carballo, D; Gencer, B; Heg, D; Jaguszewski, M; Jakob, P; Jüni, P; Klingenberg, R; Landmesser, U; Lüscher, TF; Mach, F; Maier, W; Matter, CM; Meier, B; Nanchen, D; Räber, L; Rodondi, N; Roffi, M; Stähli, BE; Stefanini, GG; Templin, C; Vogt, P; Windecker, S	1
Chen, L; Liu, D; Liu, Y; Tao, Z; Xia, G; Zhi, S	1
Bode, C; Cohen, M; Fox, K; Gibson, CM; Halperin, J; Husted, S; Lip, GY; Mehran, R; Peterson, E; van Eickels, M; Verheugt, F; Wildgoose, P	1
Liakishev, AA	1
Chen, HB; Huang, BY; Liang, HB; Liu, XW; Xiu, J; Zhang, XL; Zhang, XY	1
Alexopoulos, D; Bhatt, DL; Hamm, CW; Steg, PG; Stone, GW	1
Ahsan, CH; Ali, ML; Amin, MN; Chowdhury, MZ; Haq, MM; Karim, MR; Khan, SR; Mansur, M; Millat, MH; Rashid, MA	1
Bangalore, S; Bavishi, C; Messerli, FH; Panwar, S	1
Desch, S; Eitel, I; Empen, K; Ferenc, M; Fuernau, G; Hambrecht, R; Hausleiter, J; Hennersdorf, M; Limbourg, T; Neumann, FJ; Olbrich, HG; Orban, M; Pöss, J; Richardt, G; Schneider, S; Schuler, G; Thiele, H; Werdan, K; Zeymer, U	1
Fawcett, JP; Gu, J; Liu, M; Meng, X; Su, C; Wang, H; Xu, X; Yang, Y; Yang, Z; Zhao, X	1
Ji, JZ; Jia, YM; Tai, T; Xie, HG	1
Grobbee, DE; Heerspink, HJL; Koomen, JV; Lincoff, AM; Nicholls, SJ; Schrieks, IC; Schwartz, GG; Stevens, J; Svensson, A; Wedel, H; Weichert, A	1
Chen, H; Chen, W; Gong, Y; Lai, X; Li, H; Li, X; Li, Y; Liu, C; Liu, X; Liu, Y; Sheng, L; Sun, H; Xu, H; Yang, J; Yang, M; Yuan, F	1
Cao, X; Gu, J; Li, X; Liu, P; Miao, Y; Sun, D; Xu, Z; Zhang, J	1
Bian, YC; Diao, XX; Gan, HX; Gong, YC; Lai, XJ; Li, YG; Liu, XF; Liu, YQ; Ma, S; Miao, LY; Sun, HB; Zhan, Y; Zhang, H; Zheng, YD; Zhong, DF	1
Cai, D; Cao, X; Chen, C; Chen, L; Gao, M; Gu, J; Li, X; Liu, S; Liu, Y; Miao, Y; Niu, J; Sun, Y; Wu, T; Xu, Z	1
Gong, Y; He, Y; Lai, X; Li, YG; Liu, X; Liu, Y; Sun, H; Yan, X; Zhang, EY; Zhang, L	1
Huang, C; Li, L; Li, Y; Liu, L; Liu, W; Yuan, J; Zhang, S	1

Reviews

185 review(s) available for clopidogrel and thiophenes

Article	Year
Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Seminars in thrombosis and hemostasis, 2005, Volume: 31, Issue:2 Topics: Adenosine Diphosphate; Adult; Animals; Aspirin; Biotransformation; Clinical Trials, Phase I as Topic; Clopidogrel; Collagen; Drug Evaluation, Preclinical; Drug Synergism; Fibrinolytic Agents; Hemostasis; Humans; Male; Membrane Proteins; Molecular Structure; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Pyridines; Rats; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Thrombin; Thrombosis; Ticlopidine	2005
Aspirin and clopidogrel resistance: consideration and management. Journal of interventional cardiology, 2006, Volume: 19, Issue:5 Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Restenosis; Drug Resistance; Humans; Membrane Proteins; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine	2006
Prasugrel. Expert opinion on investigational drugs, 2006, Volume: 15, Issue:12 Topics: Adenosine Diphosphate; Animals; Aspirin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Clopidogrel; Collagen; Coronary Disease; Drug Evaluation, Preclinical; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Drugs, Investigational; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Pyridines; Rats; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2006
Platelet P2 receptors: old and new targets for antithrombotic drugs. Expert review of cardiovascular therapy, 2007, Volume: 5, Issue:1 Topics: Adenosine; Adenosine Monophosphate; Angina, Unstable; Animals; Blood Platelets; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Interactions; Fibrinolytic Agents; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Receptors, Purinergic P2X; Syndrome; Thiophenes; Ticagrelor; Ticlopidine	2007
Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. Thrombosis and haemostasis, 2007, Volume: 97, Issue:3 Topics: Blood Platelets; Cardiovascular Diseases; Clopidogrel; Drug Design; Drug Resistance; Drugs, Investigational; Humans; Membrane Proteins; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2007
Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis. Journal of cardiovascular pharmacology and therapeutics, 2007, Volume: 12, Issue:3 Topics: Adenosine Diphosphate; Adolescent; Adult; Aged; Bayes Theorem; Clinical Trials, Phase I as Topic; Clopidogrel; Databases, Factual; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Treatment Outcome	2007
ADP receptor antagonism: what's in the pipeline? American journal of cardiovascular drugs : drugs, devices, and other interventions, 2007, Volume: 7, Issue:6 Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Disease; Humans; Membrane Proteins; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine	2007
Will prasugrel supersede clopidogrel for acute coronary syndromes? The Medical journal of Australia, 2008, Apr-07, Volume: 188, Issue:7 Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticlopidine	2008
Prasugrel: a novel antiplatelet agent. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2008, Jun-01, Volume: 65, Issue:11 Topics: Acute Coronary Syndrome; Animals; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Thrombolytic Therapy; Ticlopidine	2008
Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion. Journal of interventional cardiology, 2008, Volume: 21, Issue:4 Topics: Acute Coronary Syndrome; Algorithms; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiovascular Agents; Clinical Trials as Topic; Clopidogrel; Emergency Treatment; Evidence-Based Medicine; Fibrinolytic Agents; Hirudins; Humans; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Hemorrhage; Practice Guidelines as Topic; Prasugrel Hydrochloride; Recombinant Proteins; Risk Assessment; Stents; Thiophenes; Thrombosis; Ticlopidine	2008
Antiplatelet drugs in cardiological practice: established strategies and new developments. Vascular health and risk management, 2008, Volume: 4, Issue:3 Topics: Atherosclerosis; Clopidogrel; Drug-Eluting Stents; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Thromboxane; Signal Transduction; Thiophenes; Thrombosis; Ticlopidine	2008
Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel? Cardiology clinics, 2008, Volume: 26, Issue:4 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine	2008
Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. Nature clinical practice. Cardiovascular medicine, 2008, Volume: 5, Issue:12 Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; History, 20th Century; History, 21st Century; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Stents; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2008
Is prasugrel more effective than clopidogrel in patients with acute coronary syndrome scheduled for PCI? American family physician, 2008, Dec-01, Volume: 78, Issue:11 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Dose-Response Relationship, Drug; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome	2008
Prasugrel development - claims and achievements. Thrombosis and haemostasis, 2009, Volume: 101, Issue:1 Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Aspirin; Blood Platelets; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Drug Administration Schedule; Drug Discovery; Drug Resistance; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Research Design; Risk Assessment; Stents; Thiophenes; Ticlopidine; Treatment Outcome	2009
Current problems, new opportunities and future directions of anti-platelet therapy - increasing role of novel antiplatelet agents in cardiovascular diseases. Recent patents on cardiovascular drug discovery, 2009, Volume: 4, Issue:1 Topics: Adenosine; Adenosine Monophosphate; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Humans; Imines; Lactones; Patents as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptor, PAR-1; Receptors, Purinergic P2Y12; Receptors, Thrombin; Thiophenes; Ticagrelor; Ticlopidine	2009
Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice. Critical pathways in cardiology, 2009, Volume: 8, Issue:1 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Coronary Angiography; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Severity of Illness Index; Survival Analysis; Thiophenes; Thromboembolism; Ticlopidine; Treatment Outcome	2009
Response variability and the role of platelet function testing. The Journal of invasive cardiology, 2009, Volume: 21, Issue:4 Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2009
Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention. Expert review of cardiovascular therapy, 2009, Volume: 7, Issue:4 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2009
New antiplatelet drugs: beyond aspirin and clopidogrel. International journal of clinical practice, 2009, Volume: 63, Issue:5 Topics: Adenosine; Adenosine Monophosphate; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Drug Design; Humans; Imines; Lactones; Naphthalenes; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propionates; Purinergic P2 Receptor Antagonists; Pyridines; Thiophenes; Ticagrelor; Ticlopidine	2009
Critical review of prasugrel for formulary decision makers. Journal of managed care pharmacy : JMCP, 2009, Volume: 15, Issue:4 Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Drug Interactions; Formularies, Hospital as Topic; Humans; Managed Care Programs; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Thiophenes; Ticlopidine	2009
Prasugrel for the treatment of patients with acute coronary syndrome. Vascular health and risk management, 2009, Volume: 5, Issue:1 Topics: Acute Coronary Syndrome; Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Treatment Outcome	2009
Management of patients with high gastrointestinal risk on antiplatelet therapy. Gastroenterology clinics of North America, 2009, Volume: 38, Issue:2 Topics: Aspirin; Clopidogrel; Gastrointestinal Hemorrhage; Humans; Peptic Ulcer; Peptic Ulcer Hemorrhage; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Risk Factors; Thiophenes; Ticlopidine	2009
Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention. Future cardiology, 2009, Volume: 5, Issue:3 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Resistance; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticlopidine	2009
Bedside evaluation of thienopyridine antiplatelet therapy. Circulation, 2009, May-19, Volume: 119, Issue:19 Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Clinical Trials as Topic; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Resistance; Drug Therapy, Combination; Humans; Mass Screening; Myocardial Infarction; Nephelometry and Turbidimetry; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Point-of-Care Systems; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Thrombelastography; Ticlopidine; United States	2009
Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel. Vascular health and risk management, 2009, Volume: 5, Issue:1 Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Diabetes Complications; Drug Resistance; Drug Therapy, Combination; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Stents; Thiophenes; Ticlopidine; Treatment Outcome	2009
Review of prasugrel for the secondary prevention of atherothrombosis. Journal of managed care pharmacy : JMCP, 2009, Volume: 15, Issue:5 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atherosclerosis; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Thrombosis; Ticlopidine	2009
Aggressive chronic platelet inhibition with prasugrel and increased cancer risks: revising oral antiplatelet regimens? Fundamental & clinical pharmacology, 2009, Volume: 23, Issue:4 Topics: Animals; Aspirin; Clopidogrel; Colonic Neoplasms; Gastrointestinal Hemorrhage; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine	2009
Diabetes and acute coronary syndromes. Best practice & research. Clinical endocrinology & metabolism, 2009, Volume: 23, Issue:3 Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Blood Glucose; Clopidogrel; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Enoxaparin; Hirudins; Humans; Hypoglycemic Agents; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Recombinant Proteins; Thiophenes; Thrombosis; Ticlopidine	2009
[Prodrug activation as a crucial difference. Prasugrel - a new ADP receptor antagonist]. Pharmazie in unserer Zeit, 2009, Volume: 38, Issue:4 Topics: Animals; Biotransformation; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Thiophenes; Thrombosis; Ticlopidine	2009
[Technological and biopharmaceutical aspects. Antiplatelet agents for oral administration]. Pharmazie in unserer Zeit, 2009, Volume: 38, Issue:4 Topics: Administration, Oral; Animals; Aspirin; Clopidogrel; Dipyridamole; Humans; Patents as Topic; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2009
Improving adjunctive pharmacotherapy for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: beyond the HORIZONS-AMI trial. Reviews in cardiovascular medicine, 2009,Spring, Volume: 10, Issue:2 Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Chemotherapy, Adjuvant; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Heparin; Hirudins; Humans; Myocardial Infarction; Peptide Fragments; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Recombinant Proteins; Risk Assessment; Thiophenes; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome	2009
P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. European heart journal, 2009, Volume: 30, Issue:16 Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 Enzyme System; Humans; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Thiophenes; Ticlopidine	2009
Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects. Platelets, 2009, Volume: 20, Issue:5 Topics: Adult; Clopidogrel; Coronary Artery Disease; Data Collection; Female; Humans; Kinetics; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Young Adult	2009
Prasugrel: a review of its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Drugs, 2009, Aug-20, Volume: 69, Issue:12 Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Blood Loss, Surgical; Clopidogrel; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine; Tissue Distribution; Young Adult	2009
Challenges in oral antiplatelet therapy: ST-segment elevation myocardial infarction. The American journal of cardiology, 2009, Sep-07, Volume: 104, Issue:5 Suppl Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration Schedule; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2009
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet (London, England), 2009, Sep-19, Volume: 374, Issue:9694 Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Proton Pump Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticlopidine; Treatment Outcome	2009
Prasugrel (Effient) vs. clopidogrel (Plavix). The Medical letter on drugs and therapeutics, 2009, Sep-07, Volume: 51, Issue:1320 Topics: Animals; Clopidogrel; Drug Approval; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine; United States	2009
Dual antiplatelet therapy in coronary artery disease: a case-based approach. Cleveland Clinic journal of medicine, 2009, Volume: 76, Issue:11 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Thiophenes; Ticlopidine	2009
Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Vascular health and risk management, 2009, Volume: 5 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome	2009
Advances in antiplatelet treatment for acute coronary syndromes. Heart (British Cardiac Society), 2010, Volume: 96, Issue:9 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Forecasting; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2010
Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors? Medical science monitor : international medical journal of experimental and clinical research, 2009, Volume: 15, Issue:12 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Biotransformation; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine	2009
Prasugrel: a critical comparison with clopidogrel. Pharmacotherapy, 2009, Volume: 29, Issue:12 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Animals; Clinical Trials as Topic; Clopidogrel; Drug Inverse Agonism; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; United States	2009
Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. Journal of clinical pharmacology, 2010, Volume: 50, Issue:2 Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticlopidine	2010
Update on antiplatelet therapy in acute coronary syndromes: what do new drugs bring into clinical practice? American journal of cardiovascular drugs : drugs, devices, and other interventions, 2009, Volume: 9 Suppl 1 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticagrelor; Ticlopidine	2009
Prasugrel: Clinical development and therapeutic application. Advances in therapy, 2009, Volume: 26, Issue:11 Topics: Acute Coronary Syndrome; Angioplasty; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Thrombosis; Ticlopidine	2009
Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases. British journal of pharmacology, 2010, Feb-01, Volume: 159, Issue:3 Topics: Adenosine; Adenosine Monophosphate; Benzofurans; Blood Platelets; Carbamates; Clinical Trials as Topic; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Receptor, PAR-1; Receptors, Proteinase-Activated; Thiophenes; Ticagrelor; Ticlopidine; von Willebrand Factor	2010
State of the art of new P2Y12 antagonists. Internal and emergency medicine, 2010, Volume: 5, Issue:5 Topics: Adenosine; Adenosine Monophosphate; Clopidogrel; Humans; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine	2010
What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel. QJM : monthly journal of the Association of Physicians, 2010, Volume: 103, Issue:6 Topics: Clopidogrel; Drug Evaluation, Preclinical; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Risk Factors; Thiophenes; Ticlopidine	2010
Preventing serious sequelae after an acute coronary syndrome: the consequences of thrombosis versus bleeding with antiplatelet therapy. Journal of cardiovascular pharmacology, 2010, Volume: 55, Issue:6 Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Thrombosis; Ticlopidine	2010
Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2010, Volume: 16, Issue:2 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials, Phase III as Topic; Clopidogrel; Drug Evaluation, Preclinical; Drug Therapy, Combination; Hemorrhage; Humans; Ischemia; Kidney Failure, Chronic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2010
Management of antiplatelet therapy during acute percutaneous coronary intervention: new strategies and therapeutics. Annals of the Academy of Medicine, Singapore, 2010, Volume: 39, Issue:3 Topics: Adenosine; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Therapy, Combination; Electrocardiography; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine	2010
The role of antiplatelet therapy in the secondary prevention of coronary artery disease. Current opinion in cardiology, 2010, Volume: 25, Issue:4 Topics: Adenosine; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Interactions; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Secondary Prevention; Thiophenes; Thromboxane A2; Ticagrelor; Ticlopidine	2010
Diabetes and the platelet: toward new therapeutic paradigms for diabetic atherothrombosis. Atherosclerosis, 2010, Volume: 212, Issue:2 Topics: Acute Coronary Syndrome; Apoptosis; Aspirin; Blood Platelets; Clopidogrel; Diabetes Complications; Diabetes Mellitus; Glycoproteins; Humans; Models, Biological; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Thiophenes; Thromboplastin; Thrombosis; Ticlopidine	2010
[Extent of platelet aggregation inhibition and clinical events: new evidence with prasugrel]. Giornale italiano di cardiologia (2006), 2010, Volume: 11, Issue:2 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Treatment Outcome	2010
Antiplatelet therapy in percutaneous coronary intervention: recent advances in oral antiplatelet agents. Current opinion in cardiology, 2010, Volume: 25, Issue:4 Topics: Adenosine; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine	2010
Acute coronary syndrome in the patient with diabetes: is the management different? Current cardiology reports, 2010, Volume: 12, Issue:4 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel; Diabetes Mellitus; Drug-Eluting Stents; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticlopidine	2010
Implementing genotype-guided antithrombotic therapy. Future cardiology, 2010, Volume: 6, Issue:3 Topics: Anticoagulants; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 4; Dose-Response Relationship, Drug; Genetic Privacy; Genotype; Health Policy; Humans; Mixed Function Oxygenases; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2 Receptor Antagonists; Thiophenes; Ticlopidine; Vitamin K Epoxide Reductases; Warfarin	2010
The year in interventional cardiology. Journal of the American College of Cardiology, 2010, May-18, Volume: 55, Issue:20 Topics: Adenosine; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Coronary Angiography; Coronary Disease; Coronary Occlusion; Coronary Restenosis; Drug-Eluting Stents; Foramen Ovale, Patent; Hospital Mortality; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Radiology, Interventional; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine; Treatment Outcome	2010
Dosing strategies for antiplatelet therapy in percutaneous coronary intervention. Hospital practice (1995), 2010, Volume: 38, Issue:2 Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Protocols; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Risk Assessment; Risk Factors; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome	2010
What goes into a major acute coronary syndrome trial and what will future trials look like? Current cardiology reports, 2010, Volume: 12, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clinical Trials as Topic; Clopidogrel; Cyclic N-Oxides; Eptifibatide; Heart Diseases; Humans; Peptides; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Research Design; Research Support as Topic; Risk Factors; Sample Size; Thiophenes; Ticagrelor; Ticlopidine; United Kingdom	2010
Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention. Health technology assessment (Winchester, England), 2010, Volume: 14 Suppl 1 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Cost-Benefit Analysis; Humans; Models, Economic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quality of Life; Quality-Adjusted Life Years; Risk Assessment; Thiophenes; Ticlopidine; United Kingdom	2010
New antithrombotic agents--insights from clinical trials. Nature reviews. Cardiology, 2010, Volume: 7, Issue:9 Topics: Adenosine; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Coumarins; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Thromboembolism; Ticagrelor; Ticlopidine	2010
[Antiplatelet therapy in coronary heart disease. Some problems and achivements]. Kardiologiia, 2010, Volume: 50, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Resistance; Gastrointestinal Hemorrhage; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Genetic; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Receptor, PAR-1; Thiophenes; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration	2010
Prasugrel. Circulation, 2010, Jul-27, Volume: 122, Issue:4 Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Clopidogrel; Humans; Piperazines; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Stents; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome	2010
[Platelet inhibition with prasugrel]. Deutsche medizinische Wochenschrift (1946), 2010, Volume: 135, Issue:31-32 Topics: Acute Coronary Syndrome; Administration, Oral; Angina, Unstable; Biological Availability; Clopidogrel; Coronary Artery Disease; Humans; Metabolic Clearance Rate; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Secondary Prevention; Thiophenes; Ticlopidine	2010
Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy. Cardiovascular drugs and therapy, 2010, Volume: 24, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Disease Management; Drug Synergism; Drug Therapy, Combination; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Hirudins; Humans; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Recombinant Proteins; Thiophenes; Ticagrelor; Ticlopidine	2010
Controversies in oral antiplatelet therapy in patients undergoing aortocoronary bypass surgery. The Annals of thoracic surgery, 2010, Volume: 90, Issue:3 Topics: Administration, Oral; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Thrombosis; Ticlopidine	2010
A comparison of the metabolism of clopidogrel and prasugrel. Expert opinion on drug metabolism & toxicology, 2010, Volume: 6, Issue:11 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Carboxylic Ester Hydrolases; Clopidogrel; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Thiophenes; Thrombosis; Ticlopidine	2010
Prasugrel as antiplatelet therapy in patients with acute coronary syndromes or undergoing percutaneous coronary intervention. Critical care nurse, 2010, Volume: 30, Issue:5 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Humans; Piperazines; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine	2010
Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability. Current drug metabolism, 2010, Volume: 11, Issue:8 Topics: Animals; Biological Availability; Clopidogrel; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine	2010
Prevention of the renarrowing of coronary arteries using drug-eluting stents in the perioperative period: an update. Vascular health and risk management, 2010, Oct-05, Volume: 6 Topics: Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Thrombosis; Coronary Vessels; Drug-Eluting Stents; Humans; Myocardial Revascularization; Perioperative Care; Perioperative Period; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2010
The platelet P2Y₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects. Blood, 2011, Feb-17, Volume: 117, Issue:7 Topics: Adenosine; Adenosine Diphosphate; Animals; Blood Platelet Disorders; Blood Platelets; Clopidogrel; Female; Hemorrhage; Humans; Male; Mice; Mutation; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Signal Transduction; Thiophenes; Ticagrelor; Ticlopidine	2011
ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID Circulation, 2010, Dec-14, Volume: 122, Issue:24 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Aspirin; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Histamine H2 Antagonists; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Thienopyridines; Thiophenes; Ticlopidine	2010
Prasugrel: an efficacy and safety review of a new antiplatelet therapy option. Critical pathways in cardiology, 2010, Volume: 9, Issue:4 Topics: Acute Coronary Syndrome; American Heart Association; Angioplasty, Balloon, Coronary; Clinical Trials, Phase III as Topic; Clopidogrel; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Assessment; Thiophenes; Ticlopidine; Treatment Outcome; United States	2010
ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID The American journal of gastroenterology, 2010, Volume: 105, Issue:12 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Aspirin; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Histamine H2 Antagonists; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Thienopyridines; Thiophenes; Ticlopidine	2010
Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development. Expert opinion on investigational drugs, 2011, Volume: 20, Issue:1 Topics: Animals; Clopidogrel; Coronary Thrombosis; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine	2011
[New approaches and indications for the analysis of platelet function in cardiology]. Hamostaseologie, 2011, May-02, Volume: 31, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Hemorrhage; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2011
[Novel agents in antiplatelet therapy]. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2010, Volume: 38, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Thiophenes; Ticagrelor; Ticlopidine	2010
Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor. Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:8 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Standard of Care; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2011
The onset of inhibition of platelet aggregation with prasugrel compared with clopidogrel loading doses using gatekeeping analysis of integrated clinical pharmacology data. Journal of cardiovascular pharmacology, 2011, Volume: 57, Issue:3 Topics: Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Female; Humans; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Time Factors	2011
Antiplatelet therapy in the perioperative period. Acta anaesthesiologica Belgica, 2010, Volume: 61, Issue:3 Topics: Aspirin; Clopidogrel; Humans; Perioperative Period; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2010
[Coronary heart disease - what is of importance after coronary intervention?]. Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:5 Topics: Adenosine; Aftercare; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Schedule; Drug Approval; Drug Therapy, Combination; Drug-Eluting Stents; Gastrointestinal Hemorrhage; Humans; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Proton Pump Inhibitors; Stents; Thiophenes; Ticagrelor; Ticlopidine	2011
Pharmacokinetics, drug metabolism, and safety of prasugrel and clopidogrel. Postgraduate medicine, 2011, Volume: 123, Issue:1 Topics: Area Under Curve; Clopidogrel; Drug Interactions; Half-Life; Humans; Metabolic Clearance Rate; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2011
[Current options to manage clopidogrel poor responsiveness]. Giornale italiano di cardiologia (2006), 2010, Volume: 11, Issue:12 Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Interactions; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2010
Triple therapy in hospitalized patients: facts and controversies. Journal of hospital medicine, 2011, Volume: 6, Issue:9 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Hospitalization; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Warfarin	2011
Is prasugrel more effective than clopidogrel at preventing future cardiac events? JAAPA : official journal of the American Academy of Physician Assistants, 2011, Volume: 24, Issue:2 Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Restenosis; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2011
[Prasugrel for acute and long-term treatment of patients with acute coronary syndromes: what is state-of-the-art?]. Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:15 Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Electrocardiography; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine	2011
Triple therapy: boon or bane for high-risk CV patients? The Journal of family practice, 2011, Volume: 60, Issue:4 Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Warfarin	2011
Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate. Thrombosis and haemostasis, 2011, Volume: 105 Suppl 1 Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine	2011
Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors. Thrombosis and haemostasis, 2011, Volume: 105 Suppl 1 Topics: Adenosine; Adenosine Monophosphate; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Humans; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Protein Binding; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine	2011
[Myocardial infarction: Role of new antiplatelet agents]. Presse medicale (Paris, France : 1983), 2011, Volume: 40, Issue:6 Topics: Adenosine; Adenosine Monophosphate; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Disease Management; Drug Resistance; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Reperfusion; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine; Time Factors	2011
Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials. QJM : monthly journal of the Association of Physicians, 2011, Volume: 104, Issue:7 Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Hemorrhage; Humans; Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine	2011
[Recent advances on the studies of the platelet's inhibition and aggregation. State of the art of new P2Y12 antagonists]. Recenti progressi in medicina, 2011, Volume: 102, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Catheter Ablation; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Humans; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine	2011
Antithrombotic management for transient ischemic attack and ischemic stroke (other than atrial fibrillation). Current atherosclerosis reports, 2011, Volume: 13, Issue:4 Topics: Adenosine; Aryl Hydrocarbon Hydroxylases; Brain Ischemia; Cilostazol; Clinical Trials as Topic; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Fibrinolytic Agents; Foramen Ovale, Patent; Genotype; Humans; Ischemic Attack, Transient; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Stroke; Tetrazoles; Thiophenes; Ticagrelor; Ticlopidine	2011
Beyond aspirin and clopidogrel: is there a need for additional antiplatelet therapy in ACS? Current cardiology reports, 2011, Volume: 13, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Tetrazoles; Thiophenes; Ticagrelor; Ticlopidine	2011
Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes. European heart journal, 2011, Volume: 32, Issue:18 Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine	2011
Ticagrelor for acute coronary syndrome? Drug and therapeutics bulletin, 2011, Volume: 49, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Contraindications; Drug Costs; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2011
Emerging antiplatelet therapies in percutaneous coronary intervention: a focus on prasugrel. Clinical therapeutics, 2011, Volume: 33, Issue:4 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2011
Prasugrel resistance: fact or fiction. Platelets, 2012, Volume: 23, Issue:2 Topics: Blood Platelets; Clopidogrel; Drug Resistance; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine	2012
Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose? Wiener klinische Wochenschrift, 2011, Volume: 123, Issue:15-16 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Thiophenes; Ticagrelor; Ticlopidine	2011
Genotypic and phenotypic assessment of platelet function and response to P2Y12 antagonists. Current cardiology reports, 2011, Volume: 13, Issue:5 Topics: Adenosine; Clopidogrel; Coronary Artery Disease; Female; Genetic Association Studies; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2011
Treating acute coronary syndromes with new antiplatelet drugs: the mortality issue with prasugrel and ticagrelor. Current medical research and opinion, 2011, Volume: 27, Issue:11 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Angiography; Diabetes Mellitus; Female; Humans; Hypertension; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2011
Antiplatelet options for secondary prevention in acute coronary syndromes. Expert review of cardiovascular therapy, 2011, Volume: 9, Issue:11 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Risk Factors; Secondary Prevention; Thiophenes; Ticagrelor; Ticlopidine	2011
Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease. Journal of the American College of Cardiology, 2011, Nov-22, Volume: 58, Issue:22 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chronic Disease; Clinical Trials as Topic; Clopidogrel; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Hirudins; Humans; Kidney Diseases; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Recombinant Proteins; Thiophenes; Ticagrelor; Ticlopidine; Uremia	2011
Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation: beyond clopidogrel. Current medical research and opinion, 2012, Volume: 28, Issue:2 Topics: Adenosine; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine	2012
P2Y12 platelet inhibition in clinical practice. Journal of thrombosis and thrombolysis, 2012, Volume: 33, Issue:2 Topics: Adenosine; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine	2012
Platelet-mediated thrombosis and drug-eluting stents. Circulation. Cardiovascular interventions, 2011, Dec-01, Volume: 4, Issue:6 Topics: Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Equipment Design; Humans; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticlopidine	2011
Unstable angina and non-ST elevation myocardial infarction. American journal of respiratory and critical care medicine, 2012, May-01, Volume: 185, Issue:9 Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Echocardiography; Electrocardiography; Humans; Myocardial Infarction; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine	2012
A comprehensive comparative review of adenosine diphosphate receptor antagonists. Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Drug Interactions; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2012
InforMatrix: ADP antagonists in acute coronary syndromes. Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Drug Information Services; Drugs, Generic; Evidence-Based Medicine; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2012
Quantitative comparison of clopidogrel 600 mg, prasugrel and ticagrelor, against clopidogrel 300 mg on major adverse cardiovascular events and bleeding in coronary stenting: synthesis of CURRENT-OASIS-7, TRITON-TIMI-38 and PLATO. International journal of cardiology, 2012, Jul-12, Volume: 158, Issue:2 Topics: Adenosine; Animals; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Piperazines; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine	2012
Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2012, Apr-01, Volume: 12, Issue:2 Topics: Acute Coronary Syndrome; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Secondary Prevention; Thiophenes; Ticlopidine	2012
Advances in antiplatelet therapy for acute coronary syndromes. Postgraduate medical journal, 2012, Volume: 88, Issue:1041 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Emergency Treatment; Female; Humans; Male; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2012
Acute coronary syndromes: identifying the appropriate patient for prasugrel. Postgraduate medicine, 2012, Volume: 124, Issue:2 Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Assessment; Secondary Prevention; Thiophenes; Ticlopidine	2012
Current antiplatelet options for NSTE-ACS patients. QJM : monthly journal of the Association of Physicians, 2012, Volume: 105, Issue:10 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Biological Availability; Clopidogrel; Comparative Effectiveness Research; Drug Monitoring; Drug Synergism; Drug Therapy, Combination; Electrocardiography; Humans; Pharmacovigilance; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y; Risk Assessment; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2012
Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications. Clinical pharmacokinetics, 2012, Jul-01, Volume: 51, Issue:7 Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2012
Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2013, Volume: 81, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Drug Substitution; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2013
[New antithrombotic drugs]. Duodecim; laaketieteellinen aikakauskirja, 2012, Volume: 128, Issue:7 Topics: Adenosine; Anticoagulants; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin	2012
Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2012, Volume: 35, Issue:1 Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombolytic Therapy; Ticlopidine; Warfarin	2012
Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Hospital practice (1995), 2012, Volume: 40, Issue:2 Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Resistance; Evidence-Based Medicine; Genotype; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2012
Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions. Thrombosis and haemostasis, 2012, Volume: 108, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Angioplasty; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Odds Ratio; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk; Stents; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2012
[Platelet function: new drugs, new assays : possible impacts on operative medicine?]. Der Anaesthesist, 2012, Volume: 61, Issue:6 Topics: Adenosine; Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Systems; Postoperative Complications; Postoperative Hemorrhage; Practice Guidelines as Topic; Prasugrel Hydrochloride; Predictive Value of Tests; Stents; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine	2012
Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes. Expert review of clinical pharmacology, 2012, Volume: 5, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Kaplan-Meier Estimate; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Product Surveillance, Postmarketing; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2012
Development and clinical use of prasugrel and ticagrelor. Current pharmaceutical design, 2012, Volume: 18, Issue:33 Topics: Acute Coronary Syndrome; Adenosine; Animals; Aspirin; Blood Platelets; Clopidogrel; Drug Design; Hemorrhage; Hemostasis; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2012
Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome? Current pharmaceutical design, 2012, Volume: 18, Issue:33 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clopidogrel; Coronary Thrombosis; Drug Interactions; Drug Resistance; Genotype; Hemorrhage; Humans; Patient Selection; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Predictive Value of Tests; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2012
Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents. Coronary artery disease, 2012, Volume: 23, Issue:6 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Heparin; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticlopidine; Warfarin	2012
A brief review of the past and future of platelet P2Y12 antagonist. Coronary artery disease, 2012, Volume: 23, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Stents; Sulfonamides; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine	2012
Antiplatelet therapy beyond 2012: role of personalized medicine. Polskie Archiwum Medycyny Wewnetrznej, 2012, Volume: 122, Issue:6 Topics: Adenosine; Clopidogrel; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine	2012
Importance of potent P2Y(12) receptor blockade in acute myocardial infarction: focus on prasugrel. Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:12 Topics: Clopidogrel; Costs and Cost Analysis; Drug Interactions; Humans; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2012
[Comparative antiplatelet efficacy of prasugrel and high-dose clopidogrel in patients with coronary heart disease including acute coronary syndrome]. Kardiologiia, 2012, Volume: 52, Issue:3 Topics: Clopidogrel; Coronary Disease; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome	2012
Clopidogrel in coronary artery disease: update 2012. Advances in cardiology, 2012, Volume: 47 Topics: Adenosine; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2012
Genetic considerations. Advances in cardiology, 2012, Volume: 47 Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clopidogrel; Cytochrome P-450 CYP2C19; Genome-Wide Association Study; Genotype; Humans; Liver; Pharmacogenetics; Phenotype; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine	2012
Advances in the monitoring of anti-P2Y12 therapy. Platelets, 2012, Volume: 23, Issue:7 Topics: Adenosine; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 Enzyme System; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Prodrugs; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine	2012
Thienopyridines and other ADP-receptor antagonists. Handbook of experimental pharmacology, 2012, Issue:210 Topics: Adenosine; Adenosine Monophosphate; Animals; Clopidogrel; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thienopyridines; Thiophenes; Ticagrelor; Ticlopidine	2012
New anti-platelet agents: the end of resistance? Thrombosis research, 2012, Volume: 130 Suppl 1 Topics: Adenosine; Animals; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Drug Design; Drug Resistance; Drug Therapy, Combination; Evidence-Based Medicine; Hemorrhage; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine	2012
Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR). Seminars in thrombosis and hemostasis, 2012, Volume: 38, Issue:8 Topics: Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purpura, Thrombotic Thrombocytopenic; Thienopyridines; Thiophenes; Ticlopidine	2012
Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Thrombosis and haemostasis, 2013, Volume: 109, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Stroke; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2013
Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis. Journal of thrombosis and thrombolysis, 2013, Volume: 36, Issue:3 Topics: Adenosine; Clopidogrel; Hemorrhage; Humans; Ischemia; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; PubMed; Randomized Controlled Trials as Topic; Stents; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine	2013
[Novel agents for antithrombotic therapy in cardiology]. Orvosi hetilap, 2012, Dec-23, Volume: 153, Issue:51 Topics: Adenosine; Administration, Oral; Anticoagulants; Aspirin; Clopidogrel; Coumarins; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine	2012
Metabolic differences of current thienopyridine antiplatelet agents. Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:3 Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Fibrinolytic Agents; Hemorrhage; Humans; Inactivation, Metabolic; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Thiophenes; Ticlopidine	2013
Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology. Cardiovascular drugs and therapy, 2013, Volume: 27, Issue:3 Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Stents; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2013
Antiplatelet drug use in patients with non-ST-segment elevation acute coronary syndromes. Postgraduate medicine, 2013, Volume: 125, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine	2013
Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. European heart journal, 2013, Volume: 34, Issue:23 Topics: Adenosine; Aspirin; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Clopidogrel; Dabigatran; Drug Interactions; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Warfarin	2013
A transition of P2Y12 antagonists for acute coronary syndrome: benefits, risks and costs. Journal of thrombosis and thrombolysis, 2014, Volume: 37, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine	2014
Antiplatelet therapy and cardiac surgery: review of recent evidence and clinical implications. The Canadian journal of cardiology, 2013, Volume: 29, Issue:9 Topics: Adenosine; Blood Loss, Surgical; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2013
ADP-receptor inhibitors in the perioperative period: the good, the bad, and the ugly. Journal of cardiothoracic and vascular anesthesia, 2013, Volume: 27, Issue:4 Topics: Adenosine; Cardiac Surgical Procedures; Clopidogrel; Hemorrhage; Humans; Perioperative Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Surgical Procedures, Operative; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2013
[Prominent features of management strategies in acute coronary syndromes with the new oral antiplatelet agents]. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2013, Volume: 41, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2013
New anticoagulant and antiplatelet agents: a primer for the gastroenterologist. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2014, Volume: 12, Issue:2 Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Cholangiopancreatography, Endoscopic Retrograde; Clopidogrel; Dabigatran; Drug Interactions; Fondaparinux; Gastrointestinal Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Polysaccharides; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine	2014
Pharmacokinetic considerations for antithrombotic therapies in stroke. Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:10 Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Cilostazol; Clopidogrel; Factor Xa; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Stroke; Tetrazoles; Thiophenes; Thrombin; Ticlopidine; Vitamin K	2013
Use of antiplatelet drugs in the treatment of acute coronary syndromes. Cardiovascular & hematological disorders drug targets, 2013, Volume: 13, Issue:2 Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2013
Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes. Postgraduate medicine, 2013, Volume: 125, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Decision Support Techniques; Drug Therapy, Combination; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine	2013
New antiplatelet agents and the role of platelet function testing in acute coronary syndromes. Clinical therapeutics, 2013, Volume: 35, Issue:8 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2013
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. The Canadian journal of cardiology, 2013, Volume: 29, Issue:11 Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Contraindications; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Secondary Prevention; Stents; Stroke; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine	2013
Platelet reactivity tests for assessing antiplatelet drug response: what the clinician needs to know. Expert review of cardiovascular therapy, 2013, Volume: 11, Issue:8 Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2013
[Oral antiplatelet agents can still be used along with proton pump inhibitors in spite of drug interactions]. Ugeskrift for laeger, 2013, Sep-09, Volume: 175, Issue:37 Topics: Adenosine; Administration, Oral; Aspirin; Clopidogrel; Cyclooxygenase Inhibitors; Drug Interactions; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Humans; Piperazines; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Thienopyridines; Thiophenes; Ticagrelor; Ticlopidine	2013
New antiplatelet agents for cardiovascular disease. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2013, Nov-05, Volume: 185, Issue:16 Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2013
[Thrombocyte aggregation inhibitors: what are the risks?]. Praxis, 2013, Oct-02, Volume: 102, Issue:20 Topics: Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Stents; Thiophenes; Ticagrelor; Ticlopidine	2013
Anticoagulant and antiplatelet medications encountered in emergency surgery patients: a review of reversal strategies. The journal of trauma and acute care surgery, 2013, Volume: 75, Issue:3 Topics: Anticoagulants; Aspirin; Benzimidazoles; Clopidogrel; Dabigatran; Emergencies; Enoxaparin; Fondaparinux; Heparin; Humans; Morpholines; Platelet Aggregation Inhibitors; Platelet Transfusion; Polysaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Ticlopidine; Warfarin	2013
Use of antiplatelet agents in patients with atherosclerotic disease. Postgraduate medicine, 2013, Volume: 125, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Atherosclerosis; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine	2013
Dual antiplatelet therapy -- management in general practice. Australian family physician, 2013, Volume: 42, Issue:10 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine	2013
Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis. Stroke, 2014, Volume: 45, Issue:2 Topics: Adenosine; Aged; Aspirin; Cerebral Hemorrhage; Cerebrovascular Disorders; Clopidogrel; Cohort Studies; Data Interpretation, Statistical; Drug Therapy, Combination; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Population; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Secondary Prevention; Stroke; Thiophenes; Ticagrelor; Ticlopidine; Vascular Diseases	2014
[Differentiated antiplatelet therapy for acute coronary syndromes]. Deutsche medizinische Wochenschrift (1946), 2014, Volume: 139, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Transfusion; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2014
Anticoagulation and antiplatelet therapy in acute coronary syndromes. Cleveland Clinic journal of medicine, 2014, Volume: 81, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Enoxaparin; Fondaparinux; Heparin; Hirudins; Humans; Morpholines; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin	2014
Unanswered questions in patients with concurrent atrial fibrillation and acute coronary syndrome. The American journal of cardiology, 2014, Mar-01, Volume: 113, Issue:5 Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Morpholines; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thrombosis; Ticlopidine	2014
Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials. Atherosclerosis, 2014, Volume: 233, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Stents; Stroke; Sulfonamides; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine	2014
Unravelling the smokers' paradox: cigarette smoking, high-risk coronary artery disease and enhanced clinical efficacy of oral P2Y₁₂ inhibitors. Thrombosis and haemostasis, 2014, Volume: 111, Issue:6 Topics: Adenosine; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Reduction Behavior; Smoking; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2014
Pharmacokinetic evaluation of prasugrel for the treatment of myocardial infarction. Expert opinion on drug metabolism & toxicology, 2014, Volume: 10, Issue:4 Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine	2014
New antiplatelet agents in the treatment of acute coronary syndromes. Archives of cardiovascular diseases, 2014, Volume: 107, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Coronary Thrombosis; Diabetes Complications; Hemorrhage; Humans; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Renal Insufficiency; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2014
Efficacy and safety of prasugrel in acute coronary syndrome patients. Clinical biochemistry, 2014, Volume: 47, Issue:7-8 Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2014
Dyspnea and reversibility profile of P2Y₁₂ antagonists: systematic review of new antiplatelet drugs. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2014, Volume: 14, Issue:4 Topics: Adenosine; Adenosine Monophosphate; Clopidogrel; Dyspnea; Humans; Incidence; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine	2014
[Use of antiplatelet agents in patients with chronic kidney disease: what is the evidence?]. Revue medicale suisse, 2014, Feb-26, Volume: 10, Issue:419 Topics: Adenosine; Blood Platelet Disorders; Clopidogrel; Evidence-Based Practice; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Renal Insufficiency, Chronic; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine	2014
Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors. Thrombosis and haemostasis, 2014, Volume: 112, Issue:2 Topics: Adenosine; Adenosine Monophosphate; Animals; Anti-Inflammatory Agents; Anticarcinogenic Agents; Clopidogrel; Drug Therapy, Combination; Humans; Off-Label Use; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Signal Transduction; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2014
Role of phenotypic and genetic testing in managing clopidogrel therapy. Blood, 2014, Jul-31, Volume: 124, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Substitution; Genetic Testing; Humans; Piperazines; Polymorphism, Genetic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine	2014
[Using ADP receptor antagonists in coronary heart disease and acute coronary syndrome]. Praxis, 2014, Sep-03, Volume: 103, Issue:18 Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Early Medical Intervention; General Practice; Guideline Adherence; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Stents; Thiophenes; Ticagrelor; Ticlopidine	2014
Management of acute coronary syndrome in the hospital: a focus on ACCF/AHA guideline updates to oral antiplatelet therapy. Hospital practice (1995), 2014, Volume: 42, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aspirin; Body Weight; Clopidogrel; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Quality of Health Care; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine	2014
Prasugrel hydrochloride for the treatment of acute coronary syndromes. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:4 Topics: Acute Coronary Syndrome; Animals; Aspirin; Clinical Trials, Phase III as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine	2015
Review of pharmacoeconomic evaluation of genotype-guided antiplatelet therapy. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Genotype; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Risk Assessment; Thiophenes; Ticagrelor; Ticlopidine	2015
[Anticoagulant therapy in secondary prevention of coronary events]. Vnitrni lekarstvi, 2014, Volume: 60, Issue:12 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Thiophenes; Ticlopidine; Warfarin	2014
Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity. The American journal of cardiology, 2015, Mar-15, Volume: 115, Issue:6 Topics: Adenosine; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Research Design; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2015
Clinical evidence for oral antiplatelet therapy in acute coronary syndromes. Lancet (London, England), 2015, Jul-18, Volume: 386, Issue:9990 Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Intraoperative Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Thiophenes; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2015
Meta-Analysis of Randomized Controlled Trials Comparing Risk of Major Adverse Cardiac Events and Bleeding in Patients With Prasugrel Versus Clopidogrel. The American journal of cardiology, 2015, Aug-01, Volume: 116, Issue:3 Topics: Clopidogrel; Coronary Artery Disease; Global Health; Hemorrhage; Humans; Incidence; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticlopidine	2015
Early P2Y12 inhibition in ST-segment elevation myocardial infarction: Bridging the gap. American heart journal, 2015, Volume: 170, Issue:1 Topics: Adenosine; Clopidogrel; Early Medical Intervention; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2015
Meta-Analysis of Comparison of the Newer Oral P2Y12 Inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in Patients With Non-ST-Elevation Acute Coronary Syndrome. The American journal of cardiology, 2015, Sep-01, Volume: 116, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Dose-Response Relationship, Drug; Electrocardiography; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2015
Overcoming Clopidogrel Resistance: Three Promising Novel Antiplatelet Drugs Developed in China. Journal of cardiovascular pharmacology, 2017, Volume: 70, Issue:6 Topics: Acute Coronary Syndrome; China; Clopidogrel; Drug Discovery; Drug Resistance; Humans; Phenylacetates; Platelet Aggregation Inhibitors; Prodrugs; Thiophenes; Ticlopidine	2017

Trials

121 trial(s) available for clopidogrel and thiophenes

Article	Year
Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation, 2005, Jun-28, Volume: 111, Issue:25 Topics: Adolescent; Adult; Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hemorrhage; Humans; Incidence; Male; Membrane Proteins; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2005
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. European heart journal, 2006, Volume: 27, Issue:10 Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2006
Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study. Postgraduate medical journal, 2006, Volume: 82, Issue:968 Topics: Clopidogrel; Coronary Disease; Female; Flow Cytometry; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Stents; Thiophenes; Ticlopidine	2006
Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infar American heart journal, 2006, Volume: 152, Issue:4 Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Follow-Up Studies; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Syndrome; Thiophenes; Thrombolytic Therapy; Thrombosis; Ticlopidine; Treatment Outcome	2006
A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. British journal of clinical pharmacology, 2007, Volume: 63, Issue:4 Topics: Adolescent; Adult; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2007
A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. American heart journal, 2007, Volume: 153, Issue:1 Topics: Adult; Area Under Curve; Blood Platelets; Clopidogrel; Cross-Over Studies; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticlopidine	2007
Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clinical pharmacology and therapeutics, 2007, Volume: 81, Issue:5 Topics: Adult; Area Under Curve; Clopidogrel; Cross-Over Studies; Cytochrome P-450 CYP3A Inhibitors; Double-Blind Method; Drug Interactions; Enzyme Inhibitors; Female; Humans; Ketoconazole; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2007
Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects. Journal of cardiovascular pharmacology, 2007, Volume: 49, Issue:3 Topics: Adenosine Diphosphate; Adolescent; Adult; Aspirin; Bleeding Time; Clopidogrel; Collagen; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Male; Middle Aged; Peptide Fragments; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes. The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Stroke; Thiophenes; Thrombosis; Ticlopidine	2007
Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. Journal of cardiovascular pharmacology, 2007, Volume: 50, Issue:5 Topics: Adenosine Diphosphate; Adult; Area Under Curve; Blood Platelets; Clopidogrel; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2007
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. European heart journal, 2008, Volume: 29, Issue:1 Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Treatment Outcome	2008
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Circulation, 2007, Dec-18, Volume: 116, Issue:25 Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Cross-Over Studies; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombolytic Therapy; Ticlopidine; Treatment Outcome	2007
A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry. Thrombosis and haemostasis, 2008, Volume: 99, Issue:1 Topics: Adenosine Diphosphate; Adult; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Flow Cytometry; Humans; Light; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Reproducibility of Results; Thiophenes; Ticlopidine; Time Factors	2008
The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration. Thrombosis and haemostasis, 2008, Volume: 99, Issue:2 Topics: Adult; Aspirin; Blood Coagulation Tests; Blood Platelets; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Point-of-Care Systems; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Reference Values; Reproducibility of Results; Thiophenes; Ticlopidine	2008
Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. Journal of clinical pharmacology, 2008, Volume: 48, Issue:4 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Diphosphate; Adolescent; Adult; Aged; Area Under Curve; Biological Availability; Clopidogrel; Cross-Over Studies; Drug Interactions; Female; Humans; Lansoprazole; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Thiophenes; Ticlopidine	2008
Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomi Lancet (London, England), 2008, Apr-19, Volume: 371, Issue:9621 Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome	2008
[The TRITON-TIMI 38 trial]. Giornale italiano di cardiologia (2006), 2008, Volume: 9, Issue:3 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine	2008
Approaching an age of reason with antiplatelet therapy. Lancet (London, England), 2008, Apr-19, Volume: 371, Issue:9621 Topics: Clopidogrel; Coronary Disease; Humans; Membrane Proteins; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Stents; Thiophenes; Thrombosis; Ticlopidine	2008
Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolys Journal of the American College of Cardiology, 2008, May-27, Volume: 51, Issue:21 Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Drug Therapy, Combination; Hemorrhage; Humans; Kaplan-Meier Estimate; Myocardial Infarction; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Purinergic P2 Receptor Antagonists; Stents; Thiophenes; Ticlopidine	2008
Prasugrel in the poststroke cohort of the TRITON Trial: the clear and present danger. Cerebrovascular diseases (Basel, Switzerland), 2008, Volume: 26, Issue:1 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Hemorrhage; Humans; Ischemic Attack, Transient; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Secondary Prevention; Stents; Stroke; Thiophenes; Ticlopidine; Treatment Outcome	2008
Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects. Platelets, 2008, Volume: 19, Issue:4 Topics: Adenosine Diphosphate; Adult; Aspirin; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Female; Hemorrhage; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2008
Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. European heart journal, 2008, Volume: 29, Issue:20 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Secondary Prevention; Stroke; Thiophenes; Ticlopidine; Treatment Outcome	2008
Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial I Circulation, 2008, Oct-14, Volume: 118, Issue:16 Topics: Administration, Oral; Aged; Clopidogrel; Coronary Thrombosis; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombolytic Therapy; Ticlopidine; Treatment Outcome	2008
Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. Current medical research and opinion, 2008, Volume: 24, Issue:8 Topics: Adult; Chromatography, Liquid; Clopidogrel; Cross-Over Studies; Drug Interactions; Histamine H2 Antagonists; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ranitidine; Tandem Mass Spectrometry; Thiophenes; Ticlopidine	2008
Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease. Thrombosis and haemostasis, 2008, Volume: 100, Issue:4 Topics: Adult; Aspirin; Biomarkers; Blood Platelets; Cell Communication; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Monocytes; P-Selectin; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2008
Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease. Journal of pharmacokinetics and pharmacodynamics, 2008, Volume: 35, Issue:6 Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Models, Biological; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2008
Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects. Pharmacotherapy, 2008, Volume: 28, Issue:12 Topics: Adolescent; Adult; Anticholesteremic Agents; Area Under Curve; Atorvastatin; Chromatography, Liquid; Clopidogrel; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Interactions; Epistaxis; Heptanoic Acids; Humans; Liver; Male; Metabolic Clearance Rate; Middle Aged; Molecular Structure; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrroles; Tandem Mass Spectrometry; Thiophenes; Ticlopidine; United Kingdom; Young Adult	2008
Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. Journal of the American College of Cardiology, 2008, Dec-09, Volume: 52, Issue:24 Topics: Adult; Aged; Clopidogrel; Comorbidity; Coronary Artery Disease; Diabetes Complications; Double-Blind Method; Drug Resistance; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prevalence; Pyridines; Thiophenes; Ticlopidine; Treatment Failure; Treatment Outcome	2008
Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin. American heart journal, 2009, Volume: 157, Issue:3 Topics: Anticoagulants; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Male; Optical Rotation; Phosphorylation; Piperazines; Point-of-Care Systems; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665 Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Endpoint Determination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2009
Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice. Critical pathways in cardiology, 2009, Volume: 8, Issue:1 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Coronary Angiography; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Severity of Illness Index; Survival Analysis; Thiophenes; Thromboembolism; Ticlopidine; Treatment Outcome	2009
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. European heart journal, 2009, Volume: 30, Issue:14 Topics: Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Disease; Cytochrome P-450 CYP2C19; Drug Interactions; Female; Genetic Variation; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2009
Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. European heart journal, 2009, Volume: 30, Issue:14 Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Clopidogrel; Female; Humans; Male; Microfilament Proteins; Middle Aged; Myocardial Infarction; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2009
Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardi Circulation, 2009, Jun-02, Volume: 119, Issue:21 Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel; Combined Modality Therapy; Creatine Kinase, MB Form; Death, Sudden, Cardiac; Double-Blind Method; Humans; Incidence; Kaplan-Meier Estimate; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Thiophenes; Ticlopidine; Time Factors; Troponin T	2009
The FDA prasugrel review: adjudication of myocardial infarction controversy. Cardiology, 2009, Volume: 114, Issue:2 Topics: Acute Coronary Syndrome; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Incidence; Male; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prognosis; Risk Assessment; Survival Analysis; Thiophenes; Ticlopidine; Treatment Outcome; United States; United States Food and Drug Administration	2009
The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Pla Journal of the American College of Cardiology, 2009, Aug-18, Volume: 54, Issue:8 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Stents; Stroke; Thiophenes; Ticlopidine	2009
Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitio American heart journal, 2009, Volume: 158, Issue:3 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2009
Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Thrombosis and haemostasis, 2010, Volume: 103, Issue:1 Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Paris; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome	2010
Reducing cardiac ischemic events in patients with ACS: prasugrel versus clopidogrel. Commentary. Postgraduate medicine, 2010, Volume: 122, Issue:1 Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Confidence Intervals; Double-Blind Method; Drug Therapy, Combination; Humans; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticlopidine	2010
Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial. Clinical therapeutics, 2010, Volume: 32, Issue:2 Topics: Administration, Oral; Adult; Asian People; Blood Platelets; Cell Adhesion Molecules; China; Clopidogrel; Female; Flow Cytometry; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Singapore; Thiophenes; Ticlopidine; White People; Young Adult	2010
Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. Journal of thrombosis and haemostasis : JTH, 2010, Volume: 8, Issue:8 Topics: Aged; Angina, Unstable; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cohort Studies; Cytochrome P-450 CYP2C19; Genetic Variation; Genotype; Humans; Middle Aged; Myocardial Infarction; Pharmacogenetics; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk; Thiophenes; Ticlopidine; Treatment Outcome	2010
Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage American heart journal, 2010, Volume: 160, Issue:1 Topics: Administration, Oral; Aged; Angina, Unstable; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Follow-Up Studies; Global Health; Humans; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Survival Rate; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome	2010
Prasugrel versus clopidogrel in Asian patients with acute coronary syndromes: design and rationale of a multi-dose, pharmacodynamic, phase 3 clinical trial. Current medical research and opinion, 2010, Volume: 26, Issue:9 Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Algorithms; Asian People; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Thiophenes; Ticlopidine; Young Adult	2010
Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. Journal of the American College of Cardiology, 2010, Sep-21, Volume: 56, Issue:13 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2010
Antagonism of P2Y₁₂ reduces physiological thromboxane levels. Platelets, 2010, Volume: 21, Issue:8 Topics: Adenosine Diphosphate; Adolescent; Adult; Animals; Blood Platelets; Clopidogrel; Female; Humans; Male; Mice; Mice, Knockout; Middle Aged; Pilot Projects; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Thromboxanes; Ticlopidine; Young Adult	2010
Safety and efficacy of prasugrel compared with clopidogrel in different regions of the world. International journal of cardiology, 2012, Mar-22, Volume: 155, Issue:3 Topics: Acute Coronary Syndrome; Cause of Death; Clopidogrel; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Global Health; Humans; Incidence; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Thiophenes; Ticlopidine; Treatment Outcome	2012
Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. BMC medicine, 2011, Jan-12, Volume: 9 Topics: Aspirin; Clopidogrel; Demography; Drug Resistance; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Receptors, Purinergic P2; Risk Factors; Thiophenes; Ticlopidine	2011
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. European heart journal, 2011, Volume: 32, Issue:7 Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Thiophenes; Ticlopidine; Treatment Outcome; Young Adult	2011
Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C192 genotyping. JACC. Cardiovascular interventions, 2011, Volume: 4, Issue:4* Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chi-Square Distribution; Clopidogrel; Cross-Over Studies; Cytochrome P-450 CYP2C19; Drug Resistance; Drug Therapy, Combination; Female; Genotype; Greece; Humans; Least-Squares Analysis; Male; Middle Aged; Phenotype; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymerase Chain Reaction; Prasugrel Hydrochloride; Predictive Value of Tests; Prospective Studies; Risk Assessment; Risk Factors; Single-Blind Method; Stents; Thiophenes; Ticlopidine; Treatment Outcome	2011
Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON- Circulation, 2011, Jun-14, Volume: 123, Issue:23 Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Thrombolytic Therapy; Ticlopidine	2011
Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants. British journal of clinical pharmacology, 2012, Volume: 73, Issue:1 Topics: Adult; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Clopidogrel; Cross-Over Studies; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Male; Pedigree; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Young Adult	2012
Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. Thrombosis and haemostasis, 2011, Volume: 106, Issue:2 Topics: Adenosine Diphosphate; Aged; Clopidogrel; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Platelet Activating Factor; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2011
Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy. American heart journal, 2011, Volume: 162, Issue:3 Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Cytochrome P-450 CYP1A2; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Smoking; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome	2011
Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel. American heart journal, 2011, Volume: 162, Issue:4 Topics: Aged; Chronic Disease; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Female; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Single-Blind Method; Thiophenes; Ticlopidine; Treatment Outcome	2011
Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity. Journal of thrombosis and haemostasis : JTH, 2011, Volume: 9, Issue:12 Topics: Aged; Blood Platelets; Clopidogrel; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Renal Dialysis; Single-Blind Method; Thiophenes; Ticlopidine	2011
Pharmacodynamic assessment of a novel P2Y12 receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary intervention. Thrombosis research, 2012, Volume: 129, Issue:5 Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Female; Humans; Japan; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Young Adult	2012
A prospective randomized trial comparing the recovery of platelet function after loading dose administration of prasugrel or clopidogrel. Platelets, 2013, Volume: 24, Issue:1 Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Treatment Outcome	2013
Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOppin JACC. Cardiovascular interventions, 2012, Volume: 5, Issue:3 Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Italy; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Predictive Value of Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine	2012
Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet (London, England), 2012, May-05, Volume: 379, Issue:9827 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genetic Carrier Screening; Genetic Testing; Genotype; Humans; Loss of Heterozygosity; Male; Middle Aged; Pharmacogenetics; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Point-of-Care Systems; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine	2012
A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity Journal of the American College of Cardiology, 2012, Jun-12, Volume: 59, Issue:24 Topics: Aged; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine	2012
Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. Journal of the American College of Cardiology, 2012, Jul-31, Volume: 60, Issue:5 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Cause of Death; Chest Tubes; Clopidogrel; Cohort Studies; Combined Modality Therapy; Coronary Artery Bypass; Drug Administration Schedule; Drug Therapy, Combination; Erythrocyte Transfusion; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Retrospective Studies; Risk Adjustment; Thiophenes; Ticlopidine	2012
Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study. International journal of cardiology, 2013, Sep-01, Volume: 167, Issue:5 Topics: Aged; Aged, 80 and over; Clopidogrel; Cohort Studies; Electrodes, Implanted; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Prospective Studies; Thiophenes; Ticlopidine; Treatment Outcome	2013
Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial. Journal of the American College of Cardiology, 2012, Jun-19, Volume: 59, Issue:25 Topics: Adult; Aged; Aspirin; Blood Loss, Surgical; Blood Platelets; Clopidogrel; Confounding Factors, Epidemiologic; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2012
Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. Journal of the American College of Cardiology, 2012, Jul-17, Volume: 60, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Cross-Over Studies; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2012
Angiographic and platelet reactivity outcomes with prasugrel 60 mg pretreatment and clopidogrel 600 mg pretreatment in primary percutaneous coronary intervention. Journal of thrombosis and thrombolysis, 2012, Volume: 34, Issue:4 Topics: Adult; Aged; Asian People; Clopidogrel; Cohort Studies; Coronary Thrombosis; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Preoperative Care; Singapore; Thiophenes; Ticlopidine	2012
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. The New England journal of medicine, 2012, Oct-04, Volume: 367, Issue:14 Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Stroke; Thiophenes; Ticlopidine	2012
Prasugrel versus high dose clopidogrel to overcome early high on clopidogrel platelet reactivity in patients with ST elevation myocardial infarction. Cardiovascular drugs and therapy, 2012, Volume: 26, Issue:5 Topics: Aged; Blood Platelets; Clopidogrel; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine	2012
Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial. Circulation. Cardiovascular interventions, 2012, Volume: 5, Issue:5 Topics: Aged; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Cytochrome P-450 CYP2C19; Drug Substitution; Female; Genotype; Humans; Male; Middle Aged; Myocardial Ischemia; Percutaneous Coronary Intervention; Phenotype; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Rome; Thiophenes; Ticlopidine; Treatment Outcome	2012
Randomized comparison of new dual-antiplatelet therapy (aspirin, prasugrel) and triple-antiplatelet therapy (aspirin, clopidogrel, cilostazol) using P2Y12 point-of-care assay in patients with STEMI undergoing primary PCI. International journal of cardiology, 2013, Sep-20, Volume: 168, Issue:1 Topics: Adult; Aged; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Point-of-Care Systems; Prasugrel Hydrochloride; Prospective Studies; Receptors, Purinergic P2Y12; Tetrazoles; Thiophenes; Ticlopidine	2013
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. JAMA, 2012, Nov-07, Volume: 308, Issue:17 Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Myocardial Ischemia; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Stroke; Thiophenes; Ticlopidine; Treatment Outcome	2012
Bedside monitoring to adjust antiplatelet therapy for coronary stenting. The New England journal of medicine, 2012, Nov-29, Volume: 367, Issue:22 Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Point-of-Care Systems; Prasugrel Hydrochloride; Pyridines; Retreatment; Stents; Thiophenes; Ticlopidine	2012
A randomized comparison of platelet reactivity in patients after treatment with various commercial clopidogrel preparations: the CLO-CLO trial. Archives of cardiovascular diseases, 2012, Volume: 105, Issue:11 Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Clopidogrel; Cross-Over Studies; Drugs, Generic; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Patient Selection; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Single-Blind Method; Stents; Therapeutic Equivalency; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome	2012
Selecting antiplatelet therapy at the time of percutaneous intervention for an acute coronary syndrome: weighing the benefits and risks of prasugrel versus clopidogrel. Circulation. Cardiovascular quality and outcomes, 2013, Jan-01, Volume: 6, Issue:1 Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Models, Statistical; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Stroke; Thiophenes; Ticlopidine; Treatment Outcome	2013
Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study. Thrombosis and haemostasis, 2013, Volume: 109, Issue:2 Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Cytochrome P-450 CYP2C19; Double-Blind Method; Drug Substitution; Female; Genotype; Humans; Male; Microfilament Proteins; Middle Aged; Pharmacogenetics; Phenotype; Phosphoproteins; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine; Treatment Outcome	2013
Pharmacodynamic effect of prasugrel 5 mg vs clopidogrel 150 mg in elderly patients with high on-clopidogrel platelet reactivity. American heart journal, 2013, Volume: 165, Issue:1 Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Humans; Male; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Thiophenes; Ticlopidine; Treatment Outcome	2013
Pharmacodynamic comparisons for single loading doses of prasugrel (30 mg) and clopidogrel (600 mg) in healthy Korean volunteers. Circulation journal : official journal of the Japanese Circulation Society, 2013, Volume: 77, Issue:5 Topics: Adult; Analysis of Variance; Asian People; Clopidogrel; Cross-Over Studies; Humans; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Republic of Korea; Thiophenes; Ticlopidine; Time Factors; Young Adult	2013
Comparison of prasugrel and clopidogrel reloading on high platelet reactivity in clopidogrel-loaded patients undergoing percutaneous coronary intervention (PRAISE-HPR): a study protocol for a prospective randomized controlled clinical trial. Trials, 2013, Feb-28, Volume: 14 Topics: Blood Platelets; Clinical Protocols; Clopidogrel; Drug Administration Schedule; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Republic of Korea; Research Design; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome	2013
Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes. Diabetes care, 2013, Volume: 36, Issue:8 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Single-Blind Method; Thiophenes; Ticagrelor; Ticlopidine	2013
The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. Journal of the American College of Cardiology, 2013, Aug-06, Volume: 62, Issue:6 Topics: Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Smoking; Thiophenes; Ticlopidine	2013
Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients. Journal of the American College of Cardiology, 2013, Aug-13, Volume: 62, Issue:7 Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Reference Values; Severity of Illness Index; Single-Blind Method; Survival Rate; Thiophenes; Ticlopidine; Treatment Outcome	2013
Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy. Thrombosis research, 2013, Volume: 132, Issue:1 Topics: Abciximab; Acute Coronary Syndrome; Administration, Oral; Adult; Aged; Antibodies, Monoclonal; Blood Platelets; Clopidogrel; Drug Administration Routes; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine	2013
Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. Circulation, 2013, Aug-20, Volume: 128, Issue:8 Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Disease Management; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hemorrhage; Humans; Longitudinal Studies; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticlopidine; Treatment Outcome	2013
A randomized trial of platelet reactivity monitoring-adjusted clopidogrel therapy versus prasugrel therapy to reduce high on-treatment platelet reactivity. International journal of cardiology, 2013, Oct-09, Volume: 168, Issue:4 Topics: Aged; Blood Platelets; Clopidogrel; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Single-Blind Method; Thiophenes; Ticlopidine; Treatment Outcome	2013
Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. Lancet (London, England), 2013, Aug-17, Volume: 382, Issue:9892 Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Clopidogrel; Coronary Angiography; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Stroke; Thiophenes; Ticlopidine; Treatment Outcome	2013
Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE). International journal of cardiology, 2013, Oct-15, Volume: 168, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Clopidogrel; Combined Modality Therapy; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Practolol; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Thiophenes; Ticagrelor; Ticlopidine	2013
Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways. Thrombosis and haemostasis, 2013, Volume: 110, Issue:6 Topics: Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biotransformation; Blood Platelets; Cell Adhesion Molecules; Cells, Cultured; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Piperazines; Platelet Activation; Polymorphism, Genetic; Prasugrel Hydrochloride; Prospective Studies; Pyridines; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2013
Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial. Journal of cardiovascular pharmacology and therapeutics, 2013, Volume: 18, Issue:6 Topics: Acute Coronary Syndrome; Aged; Circadian Rhythm; Clopidogrel; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Thiophenes; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome	2013
Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET): Circulation. Cardiovascular interventions, 2013, Oct-01, Volume: 6, Issue:5 Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drug Dosage Calculations; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Practice Guidelines as Topic; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2013
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. European heart journal, 2014, Volume: 35, Issue:4 Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Embolism; Female; Humans; Kaplan-Meier Estimate; Male; Morpholines; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyridines; Rivaroxaban; Stroke; Thiophenes; Ticlopidine; Treatment Outcome; Warfarin	2014
Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibit Journal of the American College of Cardiology, 2014, Jan-28, Volume: 63, Issue:3 Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome	2014
Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease. Thrombosis and haemostasis, 2014, Volume: 111, Issue:2 Topics: Aspirin; Biomarkers; Blood Platelets; Body Mass Index; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Florida; Humans; Male; Microfilament Proteins; Middle Aged; Obesity; Phosphoproteins; Phosphorylation; Piperazines; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome	2014
Treatment patterns and outcomes in patients undergoing percutaneous coronary intervention treated with prasugrel or clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR]). The American journal of cardiology, 2014, Jan-01, Volume: 113, Issue:1 Topics: Acute Coronary Syndrome; Aged; Cause of Death; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Retrospective Studies; Survival Rate; Sweden; Thiophenes; Ticlopidine; Treatment Outcome	2014
Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarctio JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:12 Topics: Acute Coronary Syndrome; Aged; Calcium Channel Blockers; Clopidogrel; Double-Blind Method; Drug Interactions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Propensity Score; Proportional Hazards Models; Proton Pump Inhibitors; Risk Factors; Stroke; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome	2013
Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response--the TAILOR (Thrombocytes And IndividuaLization of ORal antiplatelet therapy in percutaneous coronary intervention) randomized trial. Platelets, 2014, Volume: 25, Issue:7 Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prognosis; Thiophenes; Ticlopidine; Treatment Outcome	2014
Detecting a thienopyridine effect by platelet reactivity assessment and its implications for risk stratification. Journal of thrombosis and haemostasis : JTH, 2014, Volume: 12, Issue:4 Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Point-of-Care Systems; Prasugrel Hydrochloride; Pyridines; Receptors, Purinergic P2Y12; Reproducibility of Results; ROC Curve; Sensitivity and Specificity; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome	2014
A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. The Journal of the Association of Physicians of India, 2013, Volume: 61, Issue:2 Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome	2013
Outcomes in patients with ST-segment elevation acute myocardial infarction treated with clopidogrel versus prasugrel (from the INFUSE-AMI trial). The American journal of cardiology, 2014, May-01, Volume: 113, Issue:9 Topics: Antithrombins; Clopidogrel; Coronary Angiography; Electrocardiography; Female; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Recombinant Proteins; Thiophenes; Ticlopidine; Treatment Outcome	2014
Comparison of prasugrel and bivalirudin vs clopidogrel and heparin in patients with ST-segment elevation myocardial infarction: Design and rationale of the Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 trial. Clinical cardiology, 2014, Volume: 37, Issue:5 Topics: Anticoagulants; Clopidogrel; Drug Therapy, Combination; Female; Heparin; Hirudins; Humans; Male; Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Recombinant Proteins; Thiophenes; Ticlopidine; Treatment Outcome	2014
Switching from high-dose clopidogrel to prasugrel in ACS patients undergoing PCI: a single-center experience. Journal of thrombosis and thrombolysis, 2014, Volume: 38, Issue:3 Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Substitution; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine	2014
Switching from clopidogrel to prasugrel in patients having coronary stent implantation. Journal of thrombosis and thrombolysis, 2014, Volume: 38, Issue:3 Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Drug Substitution; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Renal Insufficiency, Chronic; Sex Factors; Stents; Thiophenes; Thrombosis; Ticlopidine	2014
Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial. Thrombosis and haemostasis, 2014, Volume: 112, Issue:2 Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Double-Blind Method; Drug Administration Schedule; Drug Resistance; Drug Substitution; Female; Genotype; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Phenotype; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome	2014
Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. Circulation journal : official journal of the Japanese Circulation Society, 2014, Volume: 78, Issue:7 Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Asian People; Aspirin; Clopidogrel; Drug Therapy, Combination; Follow-Up Studies; Hemorrhage; Humans; Japan; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Time Factors	2014
Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction. European heart journal, 2014, Sep-07, Volume: 35, Issue:34 Topics: Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Coronary Stenosis; Drug Therapy, Combination; Early Termination of Clinical Trials; Heparin; Hirudins; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recombinant Proteins; Thiophenes; Ticlopidine; Treatment Outcome	2014
Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial. European heart journal. Acute cardiovascular care, 2014, Volume: 3, Issue:4 Topics: Angina, Unstable; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticlopidine; Treatment Outcome	2014
Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Plate JACC. Cardiovascular interventions, 2014, Volume: 7, Issue:6 Topics: Aged; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Thrombolytic Therapy; Ticlopidine; Time Factors; Treatment Outcome	2014
Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: Insights from the TRILOGY ACS trial. American heart journal, 2014, Volume: 168, Issue:1 Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prognosis; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Smoking; Survival Rate; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome; United Kingdom; United States	2014
The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease. Thrombosis and haemostasis, 2014, Sep-02, Volume: 112, Issue:3 Topics: Aged; Clinical Protocols; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Male; Middle Aged; Phenotype; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Treatment Outcome	2014
Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study. European journal of clinical pharmacology, 2014, Volume: 70, Issue:9 Topics: Adult; Aged; Anti-Ulcer Agents; Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Interactions; Female; Humans; Lansoprazole; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2014
An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel. Current medical research and opinion, 2014, Volume: 30, Issue:11 Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Stents; Stroke; Thiophenes; Ticlopidine	2014
The net clinical benefit of personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention. Clinical science (London, England : 1979), 2015, Volume: 128, Issue:2 Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Prospective Studies; Purinergic P2Y Receptor Antagonists; Regression Analysis; Thiophenes; Ticlopidine	2015
Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention. Circulation journal : official journal of the Japanese Circulation Society, 2014, Volume: 78, Issue:12 Topics: Aged; Brain Ischemia; Clopidogrel; Combined Modality Therapy; Coronary Disease; Cytochrome P-450 CYP2C19; Double-Blind Method; Elective Surgical Procedures; Female; Follow-Up Studies; Gene Frequency; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Ticlopidine	2014
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. The New England journal of medicine, 2014, Dec-04, Volume: 371, Issue:23 Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine; Time Factors	2014
Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: the ETAMI trial (early thieno JACC. Cardiovascular interventions, 2015, Volume: 8, Issue:1 Pt B Topics: Aged; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Coronary Vessels; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Microfilament Proteins; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Phosphoproteins; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome; Vascular Patency	2015
Comparison of patient intake of ticagrelor, prasugrel, or clopidogrel on restoring platelet function by donor platelets. Transfusion, 2015, Volume: 55, Issue:6 Topics: Adenosine; Adenosine Diphosphate; Aged; Blood Platelets; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; Flow Cytometry; Half-Life; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Transfusion; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2015
Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland. Heart (British Cardiac Society), 2015, Volume: 101, Issue:11 Topics: Adolescent; Adult; Aged; Cerebrovascular Disorders; Clopidogrel; Drug-Eluting Stents; Female; Guideline Adherence; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Recurrence; Risk Factors; Thiophenes; Ticlopidine; Treatment Outcome; Young Adult	2015
An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention American heart journal, 2015, Volume: 169, Issue:4 Topics: Administration, Oral; Aged; Atrial Fibrillation; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electrocardiography; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Morpholines; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Rivaroxaban; Thiophenes; Ticlopidine; Treatment Outcome; Vitamin K	2015
[Twelve or thirty months of dual antiplatelet Therapy after drug-eluting stents. Results of the DAPT trial]. Kardiologiia, 2015, Volume: 55, Issue:1 Topics: Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Ischemia; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Postoperative Care; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome	2015
Comparison of P2Y12 receptor inhibition by clopidogrel and prasugrel in patients undergoing percutaneous coronary intervention. Bangladesh Medical Research Council bulletin, 2013, Volume: 39, Issue:3 Topics: Acute Coronary Syndrome; Adult; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome	2013
ADP receptor antagonists in patients with acute myocardial infarction complicated by cardiogenic shock: a post hoc IABP-SHOCK II trial subgroup analysis. EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2016, Dec-10, Volume: 12, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Shock, Cardiogenic; Thiophenes; Ticlopidine	2016
Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial. Diabetes, obesity & metabolism, 2020, Volume: 22, Issue:1 Topics: Aged; Cardiovascular Diseases; Clopidogrel; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Interactions; Female; Heart Disease Risk Factors; Humans; Male; Middle Aged; Oxazoles; PPAR alpha; PPAR gamma; Risk Factors; Thiophenes	2020
Platelet inhibitory activity, tolerability, and safety of vicagrel, a novel thienopyridine P2Y12 inhibitor. Medicine, 2020, Volume: 99, Issue:4 Topics: Adult; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Phenylacetates; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Thiophenes; Young Adult	2020

Other Studies

233 other study(ies) available for clopidogrel and thiophenes

Article	Year
The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. British journal of pharmacology, 2000, Volume: 129, Issue:7 Topics: Adenosine Diphosphate; Administration, Oral; Animals; Arteriovenous Shunt, Surgical; Binding, Competitive; Bleeding Time; Blood Platelets; Clopidogrel; Collagen; Cyclic AMP; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrinolytic Agents; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P2; Thionucleotides; Thiophenes; Thrombin; Thrombosis; Ticlopidine; Time Factors; Tritium	2000
Prasugrel, clopidogrel, and combining Swedish apples with American oranges. European heart journal, 2006, Volume: 27, Issue:15 Topics: Clinical Trials, Phase II as Topic; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2006
Highly selective copper-catalyzed ring expansion of vinyl thiiranes: application to synthesis of biotin and the heterocyclic core of plavix. Journal of the American Chemical Society, 2007, Mar-14, Volume: 129, Issue:10 Topics: Biotin; Catalysis; Clopidogrel; Copper; Heterocyclic Compounds; Sulfides; Thiophenes; Ticlopidine; Vinyl Compounds	2007
The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. Journal of thrombosis and haemostasis : JTH, 2007, Volume: 5, Issue:7 Topics: Adenosine Diphosphate; Alprostadil; Animals; Blood Platelets; Clopidogrel; Cyclic AMP; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Rats; Rats, Sprague-Dawley; Thiophenes; Ticlopidine	2007
Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status. The American journal of cardiology, 2007, Jul-15, Volume: 100, Issue:2 Topics: Clopidogrel; Humans; Nephelometry and Turbidimetry; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Time Factors	2007
Antiplatelet agents make a comeback in ST-elevation myocardial infarction. American heart journal, 2007, Volume: 154, Issue:4 Topics: Adenosine; Antifibrinolytic Agents; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2007
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. Journal of thrombosis and haemostasis : JTH, 2007, Volume: 5, Issue:12 Topics: Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Female; Genotype; Humans; Male; Middle Aged; Mixed Function Oxygenases; Phenotype; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Reference Values; Research Design; Retrospective Studies; Thiophenes; Ticlopidine	2007
Intensifying platelet inhibition--navigating between Scylla and Charybdis. The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20 Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemia; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2007
Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species. European journal of pharmacology, 2008, Jan-28, Volume: 579, Issue:1-3 Topics: Administration, Oral; Adult; Animals; Clopidogrel; Dogs; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; In Vitro Techniques; Macaca fascicularis; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Rabbits; Rats; Rats, Sprague-Dawley; Species Specificity; Thiophenes; Thrombosis; Ticlopidine	2008
[Prasugrel, a new thienopyridine]. Hamostaseologie, 2007, Volume: 27, Issue:5 Topics: Clinical Trials, Phase II as Topic; Clopidogrel; Coronary Thrombosis; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticlopidine	2007
The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses. Platelets, 2008, Volume: 19, Issue:2 Topics: Adenosine Monophosphate; Adult; Annexin A5; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Cytoplasmic Granules; Humans; In Vitro Techniques; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2008
[Prasugrel versus clopidogrel. From the American Heart Association meeting, 2007]. Revue medicale suisse, 2008, Feb-13, Volume: 4, Issue:144 Topics: Clopidogrel; Congresses as Topic; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2008
Prasugrel versus clopidogrel. The New England journal of medicine, 2008, Mar-20, Volume: 358, Issue:12 Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Stroke; Thiophenes; Ticlopidine	2008
Prasugrel versus clopidogrel. The New England journal of medicine, 2008, Mar-20, Volume: 358, Issue:12 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk; Thiophenes; Ticlopidine	2008
Prasugrel versus clopidogrel. The New England journal of medicine, 2008, Mar-20, Volume: 358, Issue:12 Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Monitoring, Physiologic; Myocardial Infarction; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2008
Bleeding risks with prasugrel in the TRITON trial: good news ... bad news. Cardiology, 2008, Volume: 111, Issue:4 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Therapy, Combination; Hematemesis; Hematuria; Hemorrhage; Humans; Intracranial Hemorrhages; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine	2008
Excess rates of nonfatal myocardial infarction in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel (preventing clinical events or chasing enzymatic ghosts?). The American journal of cardiology, 2008, May-01, Volume: 101, Issue:9 Topics: Clinical Trials, Phase III as Topic; Clopidogrel; Dose-Response Relationship, Drug; Female; Humans; Male; Multicenter Studies as Topic; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine; Treatment Outcome	2008
A perspective on the efficacy and safety of intensive antiplatelet therapy in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. The American journal of cardiology, 2008, May-01, Volume: 101, Issue:9 Topics: Clinical Trials, Phase III as Topic; Clopidogrel; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Humans; Multicenter Studies as Topic; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Research Design; Thiophenes; Ticlopidine; Treatment Outcome	2008
The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. Journal of thrombosis and haemostasis : JTH, 2008, Volume: 6, Issue:7 Topics: Adenosine Diphosphate; Adenosine Monophosphate; Blood Platelets; Cells, Cultured; Clopidogrel; Drug Interactions; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2008
For better or for worse: the future of antiplatelet therapy. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2008, Jun-01, Volume: 65, Issue:11 Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Disease; Forecasting; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stroke; Thiophenes; Thrombolytic Therapy; Thrombosis; Ticlopidine	2008
Multiple electrode aggregometry and P2Y(12) antagonists. Thrombosis and haemostasis, 2008, Volume: 99, Issue:6 Topics: Adenosine Diphosphate; Adenosine Monophosphate; Anticoagulants; Clopidogrel; Dose-Response Relationship, Drug; Electrodes; Equipment Design; Hirudins; Humans; Peptide Fragments; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2008
Antiplatelet therapy in acute coronary syndromes. Current cardiology reports, 2008, Volume: 10, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine	2008
[Commentary to the article: Wiviott S D, Braunwald E, McCabe C H et al. Prasugrel versus clopidogrel in patients with acute coronary syndrome. N Engl J Med 2007; 357: 2001-15]. Kardiologia polska, 2008, Volume: 66, Issue:2 Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Treatment Outcome	2008
Intensive antiplatelet therapy for reduction of ischaemic events. Lancet (London, England), 2008, Aug-16, Volume: 372, Issue:9638 Topics: Clopidogrel; Humans; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine; Time Factors	2008
[Prasugrel versus Clopidogrel in patients with acute coronary syndromes. Results of the TRITON-TIMI 38 trial]. Kardiologiia, 2008, Volume: 48, Issue:8 Topics: Acute Coronary Syndrome; Clopidogrel; Double-Blind Method; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2008
Modulation of clopidogrel pharmacodynamic response. Pharmacotherapy, 2008, Volume: 28, Issue:12 Topics: Anticholesteremic Agents; Area Under Curve; Atorvastatin; Clopidogrel; Drug Interactions; Heptanoic Acids; Humans; Metabolic Clearance Rate; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrroles; Thiophenes; Ticlopidine	2008
Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel. Drug metabolism and disposition: the biological fate of chemicals, 2009, Volume: 37, Issue:3 Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2B6; Dose-Response Relationship, Drug; Humans; Lactones; Microsomes, Liver; Oxidoreductases, N-Demethylating; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2009
The pursuit of clinically relevant measures of platelet function after antiplatelet drug therapy. Journal of the American College of Cardiology, 2008, Dec-09, Volume: 52, Issue:24 Topics: Blood Platelets; Clopidogrel; Coronary Artery Disease; Diabetes Complications; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Ticlopidine; Treatment Failure	2008
Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials. Expert review of cardiovascular therapy, 2009, Volume: 7, Issue:1 Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Clinical Trials, Phase III as Topic; Clopidogrel; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine	2009
Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine. Drug metabolism and pharmacokinetics, 2008, Volume: 23, Issue:6 Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6 Inhibitors; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Oxidoreductases, N-Demethylating; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticlopidine	2008
Another view on prasugrel. Thrombosis and haemostasis, 2009, Volume: 101, Issue:1 Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Aspirin; Blood Platelets; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Drug Administration Schedule; Drug Resistance; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Research Design; Risk Assessment; Stents; Thiophenes; Ticlopidine; Treatment Outcome	2009
Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability. Thrombosis and haemostasis, 2009, Volume: 101, Issue:1 Topics: Adenosine Diphosphate; Administration, Oral; Animals; Binding, Competitive; Bleeding Time; Clopidogrel; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrinolytic Agents; Hemorrhage; Hemostasis; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Rabbits; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thionucleotides; Thiophenes; Thrombosis; Ticlopidine	2009
Facts and controversies of aspirin and clopidogrel therapy. American heart journal, 2009, Volume: 157, Issue:3 Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Blood Platelets; Brain Ischemia; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticlopidine	2009
Ischaemia versus bleeding: the art of clinical decision-making. Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665 Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Decision Making; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine	2009
Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs. Xenobiotica; the fate of foreign compounds in biological systems, 2009, Volume: 39, Issue:3 Topics: Animals; Area Under Curve; Clopidogrel; Cytochrome P-450 Enzyme System; Dogs; Hydrolysis; Male; Molecular Structure; Oxidation-Reduction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Rats; Rats, Sprague-Dawley; Thiophenes; Ticlopidine	2009
Novel antiplatelet strategies in acute coronary syndromes. Cleveland Clinic journal of medicine, 2009, Volume: 76 Suppl 1 Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clinical Trials, Phase III as Topic; Clopidogrel; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine	2009
Prasugrel STEMI subgroup analysis. Lancet (London, England), 2009, May-30, Volume: 373, Issue:9678 Topics: Clopidogrel; Data Interpretation, Statistical; Electrocardiography; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Research Design; Thiophenes; Ticlopidine; Treatment Outcome	2009
Prasugrel STEMI subgroup analysis. Lancet (London, England), 2009, May-30, Volume: 373, Issue:9678 Topics: Clopidogrel; Data Interpretation, Statistical; Drug Administration Schedule; Electrocardiography; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Research Design; Thiophenes; Ticlopidine; Treatment Outcome	2009
Prasugrel STEMI subgroup analysis. Lancet (London, England), 2009, May-30, Volume: 373, Issue:9678 Topics: Aspirin; Clopidogrel; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Thiophenes; Ticlopidine	2009
Can we override clopidogrel resistance? Circulation, 2009, Jun-02, Volume: 119, Issue:21 Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Coronary Restenosis; Drug Resistance; Genotype; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prasugrel Hydrochloride; Prodrugs; Radiography; Stents; Thiophenes; Ticlopidine	2009
Future of oral antiplatelet therapy: four challenged hypotheses. Thrombosis and haemostasis, 2009, Volume: 101, Issue:6 Topics: Adenosine; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Cost-Benefit Analysis; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Prognosis; Purinergic P2 Receptor Antagonists; Pyridines; Risk Assessment; Survival Rate; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2009
Pharmacy benefit spending poised to increase for antithrombotic drug therapy -- prasugrel versus clopidogrel. Journal of managed care pharmacy : JMCP, 2009, Volume: 15, Issue:5 Topics: Clopidogrel; Commerce; Drug Costs; Humans; Insurance, Pharmaceutical Services; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine	2009
Relevance of metabolic activation pathways: the example of clopidogrel and prasugrel. Arzneimittel-Forschung, 2009, Volume: 59, Issue:5 Topics: Animals; Biotransformation; Clopidogrel; Cytochrome P-450 Enzyme System; Genetic Variation; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2009
[Pharmazie in unserer Zeit 4/2009]. Pharmazie in unserer Zeit, 2009, Volume: 38, Issue:4 Topics: Aspirin; Atherosclerosis; Clopidogrel; Drug Resistance; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticlopidine	2009
Test before you stop. Archives of surgery (Chicago, Ill. : 1960), 2009, Volume: 144, Issue:8 Topics: Adenosine; Algorithms; Aspirin; Clinical Trials as Topic; Clopidogrel; Humans; Perioperative Care; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine	2009
Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis. Thrombosis research, 2009, Volume: 124, Issue:5 Topics: Adenosine; Animals; CHO Cells; Clopidogrel; Cricetinae; Cricetulus; Disease Models, Animal; Dogs; Hemostasis; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Rats; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine; Transfection	2009
Cardiovascular disease gets personal. Nature, 2009, Aug-20, Volume: 460, Issue:7258 Topics: Anticoagulants; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Female; Genetic Predisposition to Disease; Genetic Testing; Genetic Variation; Genome-Wide Association Study; Genomics; Humans; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Warfarin	2009
A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. Drug metabolism and disposition: the biological fate of chemicals, 2009, Volume: 37, Issue:11 Topics: Clopidogrel; Cytochrome P-450 Enzyme System; Genetic Variation; Humans; Microsomes, Liver; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticlopidine	2009
Ticagrelor--is there need for a new player in the antiplatelet-therapy field? The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2009
Risk of combining PPIs with thienopyridines: fact or fiction? Lancet (London, England), 2009, Sep-19, Volume: 374, Issue:9694 Topics: Biotransformation; Clopidogrel; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Pyridines; Thiophenes; Ticlopidine	2009
[New thrombocyte inhibitor. Fewer ischemic complications in acute coronary syndrome]. MMW Fortschritte der Medizin, 2009, Sep-03, Volume: 151, Issue:36 Topics: Acute Coronary Syndrome; Clopidogrel; Double-Blind Method; Humans; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine	2009
Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel. Xenobiotica; the fate of foreign compounds in biological systems, 2009, Volume: 39, Issue:11 Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Kinetics; Microsomes, Liver; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2009
Stent thrombosis: who's guilty? European heart journal, 2009, Volume: 30, Issue:22 Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Blood Vessel Prosthesis; Cardiology; Clinical Competence; Clopidogrel; Cytochrome P-450 CYP2C19; Drug-Eluting Stents; Graft Occlusion, Vascular; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticlopidine	2009
Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel. Prescrire international, 2009, Volume: 18, Issue:103 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Drug-Eluting Stents; Europe; Hemorrhage; Humans; Ischemic Attack, Transient; Myocardial Infarction; Neoplasms; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Recurrence; Stents; Stroke; Thiophenes; Ticlopidine; Treatment Outcome	2009
[Changing times for clopidogrel]. Medizinische Monatsschrift fur Pharmazeuten, 2009, Volume: 32, Issue:10 Topics: Clopidogrel; Drug Interactions; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2 Receptor Antagonists; Thiophenes; Ticlopidine	2009
Clopidogrel versus prasugrel: times are changing, but not for everyone. Pharmacotherapy, 2009, Volume: 29, Issue:12 Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2009
Prasugrel for acute coronary syndromes: faster, more potent, but higher bleeding risk. Cleveland Clinic journal of medicine, 2009, Volume: 76, Issue:12 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2009
Clinical trial update II: TRITON-TIMI 38 provides reassurance on concomitant use of proton pump inhibitors and thienopyridines. European heart journal, 2009, Volume: 30, Issue:23 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Interactions; Gastrointestinal Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine	2009
The TRITON versus PLATO trials: differences beyond platelet inhibition. Thrombosis and haemostasis, 2010, Volume: 103, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Drug Evaluation; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2010
Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasug Circulation, 2010, Jan-05, Volume: 121, Issue:1 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Cost-Benefit Analysis; Databases, Factual; Drug Costs; Follow-Up Studies; Hemorrhage; Hospitalization; Humans; Life Expectancy; Multicenter Studies as Topic; Myocardial Infarction; Outcome and Process Assessment, Health Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Stroke; Thiophenes; Thrombolytic Therapy; Ticlopidine; United States	2010
Ticagrelor in ACS: redefining a new standard of care? Lancet (London, England), 2010, Jan-23, Volume: 375, Issue:9711 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2010
Lack of outcome benefit and clopidogrel "resistance." The TRITON trial challenge. Thrombosis and haemostasis, 2010, Volume: 103, Issue:2 Topics: Acute Coronary Syndrome; Clopidogrel; Drug Approval; Drug Resistance; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Stroke; Survival Analysis; Thiophenes; Ticlopidine; Treatment Outcome	2010
Role of ticagrelor in clopidogrel nonresponders: resistance is futile? Circulation, 2010, Mar-16, Volume: 121, Issue:10 Topics: Adenosine; Clopidogrel; Coronary Artery Disease; Drug Resistance; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine	2010
Trial watch. DAPT study. Harvard heart letter : from Harvard Medical School, 2010, Volume: 20, Issue:5 Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2010
Delays of event adjudication in the TRITON trial. Cardiology, 2010, Volume: 115, Issue:3 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cerebral Infarction; Clopidogrel; Coronary Restenosis; Data Collection; Disease-Free Survival; Hemorrhage; Myocardial Infarction; Observer Variation; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Reproducibility of Results; Research Design; Stents; Thiophenes; Ticlopidine; Treatment Outcome; United States; United States Food and Drug Administration	2010
Prasugrel, Māori, and personalised medicine in New Zealand. The New Zealand medical journal, 2010, Mar-05, Volume: 123, Issue:1310 Topics: Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Genetic Markers; Genetic Testing; Humans; Native Hawaiian or Other Pacific Islander; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Precision Medicine; Stents; Thiophenes; Thrombosis; Ticlopidine; Vascular Diseases	2010
A comparison of the VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis. Journal of cardiovascular pharmacology, 2010, Volume: 56, Issue:1 Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aged; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Databases, Factual; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Systems; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2010
[Interview with Prof. Franz-Joseph Krozingen: Interventional cardiology on the success course]. MMW Fortschritte der Medizin, 2010, Apr-01, Volume: 152, Issue:13 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cardiology; Clinical Trials as Topic; Clopidogrel; Emergencies; Fibrinolysis; Forecasting; Humans; Length of Stay; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Stents; Thiophenes; Ticlopidine; Time Factors	2010
[Comparison of effects of prasugrel and clopidogrel in patients with acute coronary syndrome, subjected to percutaneous coronary intervention: TRITON-TIMI 38 trial]. Kardiologiia, 2010, Volume: 50, Issue:6 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug-Eluting Stents; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Stroke; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome	2010
Letter by Serebruany regarding article, "Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by O Circulation, 2010, Aug-24, Volume: 122, Issue:8 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Cost-Benefit Analysis; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombolytic Therapy; Ticlopidine; Treatment Outcome	2010
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet (London, England), 2010, Oct-16, Volume: 376, Issue:9749 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genetic Variation; Genotype; Humans; Male; Middle Aged; Pharmacogenetics; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine	2010
Response to antiplatelet treatment: from genes to outcome. Lancet (London, England), 2010, Oct-16, Volume: 376, Issue:9749 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prasugrel Hydrochloride; Stents; Thiophenes; Ticlopidine	2010
Effects of thienopyridines and thienopyrimidinones on L-type calcium current in isolated cardiomyocytes. Naunyn-Schmiedeberg's archives of pharmacology, 2010, Volume: 382, Issue:5-6 Topics: Action Potentials; Animals; Atrial Appendage; Calcium Channels, L-Type; Cells, Cultured; Clopidogrel; Guinea Pigs; Heart Ventricles; Humans; In Vitro Techniques; Myocytes, Cardiac; Patch-Clamp Techniques; Platelet Aggregation Inhibitors; Pyrimidines; Thienopyridines; Thiophenes; Ticlopidine	2010
Prasugrel as alternative treatment strategy in a case with a hypersensitivity reaction to clopidogrel. Platelets, 2011, Volume: 22, Issue:1 Topics: Aged; Angioedema; Clopidogrel; Drug Hypersensitivity; Exanthema; Fever; Humans; Male; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Tachycardia; Thiophenes; Thrombosis; Ticlopidine	2011
Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. Hospital practice (1995), 2010, Volume: 38, Issue:4 Topics: Adenosine; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2010
A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty. Journal of thrombosis and thrombolysis, 2011, Volume: 31, Issue:2 Topics: Angioplasty, Balloon, Coronary; Antineoplastic Agents; Clopidogrel; Docetaxel; Drug Resistance; Drug-Eluting Stents; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Taxoids; Thiophenes; Thrombosis; Ticlopidine	2011
Prasugrel and cancer. Archives of internal medicine, 2010, Nov-22, Volume: 170, Issue:21 Topics: Clinical Trials as Topic; Clopidogrel; Humans; Neoplasms; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2010
[Evidence-based management of ST-segment elevation myocardial infarction (STEMI). Latest guidelines of the European Society of Cardiology (ESC) 2010]. Herz, 2010, Volume: 35, Issue:8 Topics: Aftercare; Anticoagulants; Cardiovascular Agents; Clopidogrel; Combined Modality Therapy; Contraindications; Electrocardiography; Emergency Medical Services; Emergency Service, Hospital; Europe; Evidence-Based Medicine; Humans; Life Style; Myocardial Infarction; Myocardial Reperfusion; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Thrombolytic Therapy; Ticlopidine; Time Factors	2010
An algorithm for use of prasugrel (effient) in patients undergoing cardiac catheterization and percutaneous coronary intervention. Critical pathways in cardiology, 2010, Volume: 9, Issue:4 Topics: Angioplasty, Balloon, Coronary; Cardiac Catheterization; Clinical Protocols; Clinical Trials as Topic; Clopidogrel; Comparative Effectiveness Research; Guidelines as Topic; Hemorrhage; Humans; Myocardial Infarction; Patient Care Planning; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Assessment; Standard of Care; Thiophenes; Thrombolytic Therapy; Ticlopidine; Treatment Outcome	2010
Antiplatelet and antithrombotic treatment after primary percutaneous coronary intervention: balancing safety and efficacy. American heart journal, 2010, Volume: 160, Issue:6 Suppl Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration Schedule; Fibrinolytic Agents; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Safety; Secondary Prevention; Thiophenes; Ticlopidine; Treatment Outcome; Warfarin	2010
Resistance to anti-platelet agents. Thrombosis research, 2011, Volume: 127 Suppl 3 Topics: Adenosine; Aspirin; Clopidogrel; Drug Resistance; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2011
[Do genetic factors reduce the effects of clopidogrel?]. Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:15 Topics: Adenosine; Clopidogrel; Cytochrome P-450 Enzyme System; Genetic Variation; Genotype; Hemorrhage; Humans; Isoenzymes; Pharmacogenetics; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2011
[Multiple arterial thrombosis and resistance to conventional antiaggregation]. Revista espanola de cardiologia, 2011, Volume: 64, Issue:9 Topics: Aged; Angiography; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Resistance; Electrocardiography; Female; Femoral Artery; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine	2011
Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI. Clinical research in cardiology : official journal of the German Cardiac Society, 2011, Volume: 100, Issue:10 Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Cerebrovascular Disorders; Cilostazol; Clopidogrel; Drug Monitoring; Drug Resistance; Drug Substitution; Electrodes; Female; Germany; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Prospective Studies; Risk Assessment; Risk Factors; Stents; Tetrazoles; Thiophenes; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome	2011
Prasugrel as a safe alternative for clopidogrel-associated arthritis. The Journal of invasive cardiology, 2011, Volume: 23, Issue:6 Topics: Arthritis; Clopidogrel; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2011
Oral antiplatelet agents clopidogrel and prasugrel for the prevention of cardiovascular events. BMJ (Clinical research ed.), 2011, Jun-17, Volume: 342 Topics: Administration, Oral; Cardiovascular Diseases; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2011
[Specificities of diabetes in acute coronary syndromes]. Revue medicale suisse, 2011, Jun-01, Volume: 7, Issue:297 Topics: Acute Coronary Syndrome; Algorithms; Angioplasty; Anti-Inflammatory Agents, Non-Steroidal; Clopidogrel; Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combination; Enoxaparin; Evidence-Based Medicine; Fibrinolytic Agents; Heparin; Humans; Hypoglycemic Agents; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Secondary Prevention; Stents; Thiophenes; Ticlopidine; Treatment Outcome	2011
Subacute stent thrombosis owing to complete clopidogrel resistance successfully managed with prasugrel. The Journal of invasive cardiology, 2011, Volume: 23, Issue:7 Topics: Angioplasty, Balloon, Coronary; Anterior Wall Myocardial Infarction; Clopidogrel; Contraindications; Coronary Artery Disease; Drug Resistance; Drug-Eluting Stents; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Thiophenes; Thrombosis; Ticlopidine; Treatment Failure; Treatment Outcome	2011
Massive thrombus burden with recurrence of intracoronary thrombosis early after stenting and delayed onset of prasugrel action in a patient with ST-elevation myocardial infarction and cardiac shock. Thrombosis and haemostasis, 2011, Volume: 106, Issue:3 Topics: Aged; Angioplasty, Balloon, Coronary; Cardiopulmonary Resuscitation; Catecholamines; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Interactions; Electrocardiography; Female; Heart Arrest; Humans; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Recurrence; Stents; Thiophenes; Ticlopidine; Time Factors	2011
Direct vasoactive properties of thienopyridine-derived nitrosothiols. Journal of cardiovascular pharmacology, 2011, Volume: 58, Issue:5 Topics: Animals; Aorta, Thoracic; Clopidogrel; Glutathione; Guanylate Cyclase; Hydrogen-Ion Concentration; In Vitro Techniques; Luminescent Measurements; Male; Mass Spectrometry; Molecular Structure; Nitro Compounds; Oxadiazoles; Ozone; Piperazines; Prasugrel Hydrochloride; Quinoxalines; Rabbits; S-Nitrosothiols; Sodium Nitrite; Spectrophotometry, Ultraviolet; Thienopyridines; Thiophenes; Ticlopidine; Vasodilation; Vasodilator Agents	2011
Dissecting the activation of thienopyridines by cytochromes P450 using a pharmacodynamic assay in vitro. The Journal of pharmacology and experimental therapeutics, 2011, Volume: 339, Issue:2 Topics: Aryl Hydrocarbon Hydroxylases; Baculoviridae; Biosensing Techniques; Biotransformation; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Assays; Humans; Microsomes; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet-Rich Plasma; Prasugrel Hydrochloride; Thienopyridines; Thiophenes; Ticlopidine	2011
Impact of dyspnea on medical utilization and affiliated costs in patients with acute coronary syndrome. Hospital practice (1995), 2011, Volume: 39, Issue:3 Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Costs and Cost Analysis; Diagnostic Techniques and Procedures; Drug Therapy, Combination; Dyspnea; Emergency Service, Hospital; Female; Humans; Insurance Claim Review; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2011
Use of prasugrel in a patient with clopidogrel hypersensitivity. The Annals of pharmacotherapy, 2011, Volume: 45, Issue:10 Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Drug Hypersensitivity; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome	2011
Ticagrelor (Brilinta)--better than clopidogrel (Plavix)? The Medical letter on drugs and therapeutics, 2011, Sep-05, Volume: 53, Issue:1372 Topics: Adenosine; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Approval; Drug Interactions; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine; United States	2011
A case of acute stent thrombosis during treatment with the thrombopoietin receptor agonist peptide--romiplostim. Heart, lung & circulation, 2012, Volume: 21, Issue:3 Topics: Acute Disease; Aspirin; Chest Pain; Clopidogrel; Eptifibatide; Female; Humans; Middle Aged; Peptides; Piperazines; Platelet Aggregation Inhibitors; Platelet Count; Prasugrel Hydrochloride; Purpura, Thrombocytopenic, Idiopathic; Receptors, Thrombopoietin; Risk Factors; Stents; Thiophenes; Thrombosis; Ticlopidine; Ultrasonography, Interventional	2012
Allergic reaction to prasugrel and cross-reactivity with clopidogrel. International journal of cardiology, 2012, Jun-14, Volume: 157, Issue:3 Topics: Aged; Clopidogrel; Cross Reactions; Female; Humans; Hypersensitivity; Piperazines; Prasugrel Hydrochloride; Pruritus; Thiophenes; Ticlopidine	2012
Platelet function profiles in the elderly: results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity. Thrombosis and haemostasis, 2011, Volume: 106, Issue:6 Topics: Aged; Aged, 80 and over; Blood Platelets; Clinical Protocols; Clopidogrel; Drug Substitution; Female; Humans; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2011
Cost-effectiveness of prasugrel in a US managed care population. Journal of medical economics, 2012, Volume: 15, Issue:1 Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cost Control; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Humans; Interviews as Topic; Male; Managed Care Programs; Middle Aged; Models, Economic; Outcome Assessment, Health Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; United States	2012
High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study. European heart journal, 2012, Volume: 33, Issue:10 Topics: Acute Coronary Syndrome; Adult; Age Factors; Aged; Aged, 80 and over; Clopidogrel; Cross-Sectional Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Thiophenes; Ticlopidine	2012
Variability and treatment of high on-prasugrel platelet reactivity in patients with initial high on-clopidogrel platelet reactivity. International journal of cardiology, 2012, Feb-09, Volume: 154, Issue:3 Topics: Blood Platelet Disorders; Clopidogrel; Female; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine	2012
Post percutaneous coronary intervention antiplatelet therapy: current perceptions, prospects and perplexity. Cardiology journal, 2011, Volume: 18, Issue:6 Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Drug Resistance; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Metals; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prosthesis Design; Risk Assessment; Risk Factors; Stents; Tetrazoles; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome	2011
Successful use of prasugrel, an alternative antiplatelet agent, in a patient with clopidogrel allergy. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2011, Volume: 107, Issue:6 Topics: Clopidogrel; Drug Hypersensitivity; Humans; Hypersensitivity, Immediate; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2011
Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: a placebo-controlled study in rats. Thrombosis research, 2012, Volume: 130, Issue:1 Topics: Adenosine; Adenosine Diphosphate; Animals; Arteries; Clopidogrel; Muscle Contraction; Myocytes, Smooth Muscle; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Rats; Rats, Wistar; Thiophenes; Ticagrelor; Ticlopidine	2012
Toward a therapeutic window for antiplatelet therapy in the elderly. European heart journal, 2012, Volume: 33, Issue:10 Topics: Acute Coronary Syndrome; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2012
"Conversations in cardiology": How do you pick the best antiplatelet drug--clopidogrel, prasugrel, ticagrelor for your PCI patient? Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2012, Feb-01, Volume: 79, Issue:2 Topics: Adenosine; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Decision Making; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2012
New look at antiplatelet agent-related peptic ulcer: an update of prevention and treatment. Journal of gastroenterology and hepatology, 2012, Volume: 27, Issue:4 Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Interactions; Gastrointestinal Hemorrhage; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Thiophenes; Ticlopidine	2012
Desensitization to prasugrel: cardiology's increased need for allergy consultation. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2012, Volume: 108, Issue:2 Topics: Atherectomy, Coronary; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Artery Disease; Desensitization, Immunologic; Drug Dosage Calculations; Drug Hypersensitivity; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Referral and Consultation; Stents; Thiophenes; Ticlopidine	2012
Management of a hypersensitivity reaction to thienopyridines: prasugrel-induced fever and hepatitis resolved after switching to clopidogrel. Revista espanola de cardiologia (English ed.), 2012, Volume: 65, Issue:8 Topics: Adult; Clopidogrel; Coronary Artery Disease; Drug Hypersensitivity; Female; Fever; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2012
Prasugrel as a safe alternative for clopidogrel-induced polyarthralgias. Pharmacotherapy, 2012, Volume: 32, Issue:2 Topics: Arthralgia; Clopidogrel; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2012
[Optimal antiplatelet and antithrombotic therapy in patients with ST elevation myocardial infarction]. Kardiologia polska, 2012, Volume: 70, Issue:2 Topics: Abciximab; Adenosine; Antibodies, Monoclonal; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine	2012
[Letter to Kardiologia Polska concerning optimal treatment of myocardial infarction]. Kardiologia polska, 2012, Volume: 70, Issue:2 Topics: Adenosine; Clopidogrel; Cost-Benefit Analysis; Humans; Models, Theoretical; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine	2012
Overcoming clopidogrel resistance: discovery of vicagrel as a highly potent and orally bioavailable antiplatelet agent. Journal of medicinal chemistry, 2012, Apr-12, Volume: 55, Issue:7 Topics: Administration, Oral; Animals; Biological Availability; Clopidogrel; Drug Resistance; Female; In Vitro Techniques; Male; Mice; Microsomes, Liver; Phenylacetates; Platelet Aggregation Inhibitors; Prodrugs; Rats; Stereoisomerism; Structure-Activity Relationship; Thiophenes; Ticlopidine	2012
A risk-benefit assessment of prasugrel, clopidogrel, and genotype-guided therapy in patients undergoing percutaneous coronary intervention. Clinical pharmacology and therapeutics, 2012, Volume: 91, Issue:5 Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Probability; Risk Assessment; Thiophenes; Ticlopidine	2012
Cost is not a barrier to implementing clopidogrel pharmacogenetics. Pharmacotherapy, 2012, Volume: 32, Issue:4 Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombolytic Therapy; Ticlopidine	2012
Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel. Pharmacotherapy, 2012, Volume: 32, Issue:4 Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clopidogrel; Computer Simulation; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Trees; Drugs, Generic; Genotype; Hemorrhage; Humans; Models, Economic; Models, Statistical; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombolytic Therapy; Ticlopidine	2012
Suboptimal response to clopidogrel and the effect of prasugrel in acute coronary syndromes. International journal of cardiology, 2013, Aug-10, Volume: 167, Issue:3 Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; New Zealand; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome	2013
Using models to predict the future: what to do when the data run out? Clinical pharmacology and therapeutics, 2012, Volume: 91, Issue:5 Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2012
Prasugrel: a guide to its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention in the US. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2012, Jun-01, Volume: 12, Issue:3 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Economics, Pharmaceutical; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Thrombosis; Ticlopidine; United States	2012
Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel. Biopharmaceutics & drug disposition, 2012, Volume: 33, Issue:5 Topics: Clopidogrel; Drug Interactions; Humans; In Vitro Techniques; Microsomes, Liver; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Prasugrel Hydrochloride; Proton Pump Inhibitors; Thiophenes; Ticlopidine	2012
Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor. Platelets, 2012, Volume: 23, Issue:5 Topics: Adenosine; Aged; Cardiopulmonary Resuscitation; Clopidogrel; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Shock, Cardiogenic; Stents; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine	2012
CYP2C19 genotype-guided antiplatelet therapy in a patient with clopidogrel resistance. Connecticut medicine, 2012, Volume: 76, Issue:5 Topics: Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Resistance; Genotype; Humans; Male; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Ticlopidine; Treatment Outcome	2012
P2Y12 inhibitors in acute coronary syndromes: how do we choose the best drug for our patients? Thrombosis and haemostasis, 2012, Volume: 108, Issue:2 Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine	2012
Switching patients from clopidogrel to prasugrel in acute coronary syndrome: effects of prasugrel loading dose on residual platelet reactivity. Journal of thrombosis and haemostasis : JTH, 2012, Volume: 10, Issue:9 Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2012
Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes. The American journal of medicine, 2012, Volume: 125, Issue:9 Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Risk Assessment; Stroke; Thiophenes; Ticlopidine; Treatment Outcome; Warfarin	2012
A potent alternative to clopidogrel emerges. Prasugrel appears to lower heart attack risk for patients with acute coronary syndrome. Heart advisor, 2010, Volume: 13, Issue:5 Topics: Acute Coronary Syndrome; Clopidogrel; Drug Dosage Calculations; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2010
[Removal of epidural catheter under dual antiplatelet therapy following acute coronary syndrome : scenario without special consideration to the current guidelines on epidural regional anesthesia]. Der Anaesthesist, 2012, Volume: 61, Issue:8 Topics: Acute Coronary Syndrome; Analgesia, Epidural; Aspirin; Catheterization; Clopidogrel; Digestive System Surgical Procedures; Drug Interactions; Hemorrhage; Humans; Male; Middle Aged; Pain, Postoperative; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Risk; Thiophenes; Ticlopidine	2012
High frequency of CYP2C192 carriers in PCI-treated patients switched over from clopidogrel to prasugrel based on platelet function monitoring. Platelets, 2013, Volume: 24, Issue:6* Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Substitution; Heterozygote; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine	2013
Failure of high-dose clopidogrel in recurrent stent thrombosis. Singapore medical journal, 2012, Volume: 53, Issue:8 Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Drug-Eluting Stents; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine; Treatment Failure	2012
The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation. PharmacoEconomics, 2012, Nov-01, Volume: 30, Issue:11 Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Alleles; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Trees; Diagnosis-Related Groups; Drugs, Generic; Female; Genetic Testing; Hospital Costs; Hospitalization; Humans; Male; Middle Aged; Monte Carlo Method; Native Hawaiian or Other Pacific Islander; New Zealand; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Quality-Adjusted Life Years; Thiophenes; Ticlopidine	2012
Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis. The Journal of thoracic and cardiovascular surgery, 2013, Volume: 145, Issue:4 Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Bypass; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Transfusion; Prasugrel Hydrochloride; Retrospective Studies; Risk Factors; Thiophenes; Ticlopidine	2013
Residual platelet activation through protease-activated receptors (PAR)-1 and -4 in patients on P2Y12 inhibitors. International journal of cardiology, 2013, Sep-20, Volume: 168, Issue:1 Topics: Adult; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Oligopeptides; Peptide Fragments; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptor, PAR-1; Receptors, Purinergic P2Y12; Receptors, Thrombin; Thiophenes; Ticlopidine	2013
Effects of rivaroxaban, acetylsalicylic acid and clopidogrel as monotherapy and in combination in a porcine model of stent thrombosis. Journal of thrombosis and haemostasis : JTH, 2012, Volume: 10, Issue:12 Topics: Animals; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Morpholines; Platelet Aggregation; Rivaroxaban; Stents; Swine; Swine, Miniature; Thiophenes; Thrombosis; Ticlopidine	2012
Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial. Journal of the American College of Cardiology, 2012, Nov-13, Volume: 60, Issue:20 Topics: Adolescent; Adult; Aged; Blood Platelets; Body Weight; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Single-Blind Method; Thiophenes; Ticlopidine; Young Adult	2012
Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy. International journal of cardiology, 2013, Sep-20, Volume: 168, Issue:1 Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Diabetes Mellitus; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome	2013
Prevention of stent thrombosis with reduced dose of prasugrel in two patients undergoing treatment of cerebral aneurysms with pipeline embolisation devices. BMJ case reports, 2012, Oct-26, Volume: 2012 Topics: Blood Platelets; Clopidogrel; Embolization, Therapeutic; Female; Hemorrhage; Humans; Intracranial Aneurysm; Intracranial Thrombosis; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Thiophenes; Ticlopidine; Treatment Outcome	2012
Measured drug effect and cardiovascular outcomes in patients receiving platelet P2Y12 receptor antagonists: clarifying the time and place for intensive inhibition. JAMA, 2012, Nov-07, Volume: 308, Issue:17 Topics: Acute Coronary Syndrome; Clopidogrel; Female; Humans; Male; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2012
Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis. Journal of thrombosis and haemostasis : JTH, 2013, Volume: 11, Issue:1 Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Cerebrovascular Disorders; Clopidogrel; Computer Simulation; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Support Techniques; Disease-Free Survival; Drug Costs; Gene Frequency; Genetic Predisposition to Disease; Genetic Testing; Health Care Costs; Hemorrhage; Humans; Insurance, Health, Reimbursement; Kaplan-Meier Estimate; Markov Chains; Medicare; Models, Economic; Myocardial Infarction; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Quality-Adjusted Life Years; Risk Assessment; Risk Factors; Thiophenes; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome; United States	2013
Trilogy: in search of the lost ring. International journal of cardiology, 2013, Aug-20, Volume: 167, Issue:4 Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clinical Trials as Topic; Clopidogrel; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2013
Pharmacokinetics of vicagrel, a promising analog of clopidogrel, in rats and beagle dogs. Journal of pharmaceutical sciences, 2013, Volume: 102, Issue:2 Topics: Animals; Clopidogrel; Dogs; Female; Male; Phenylacetates; Rats; Rats, Sprague-Dawley; Thiophenes; Ticlopidine	2013
Clopidogrel pretreatment of patients with ST-elevation myocardial infarction does not affect platelet reactivity after subsequent prasugrel-loading: platelet reactivity in an observational study. Platelets, 2013, Volume: 24, Issue:7 Topics: Aged; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2013
Prevention of stent thrombosis with reduced dose of prasugrel in two patients undergoing treatment of cerebral aneurysms with pipeline embolisation devices. Journal of neurointerventional surgery, 2013, Sep-01, Volume: 5, Issue:5 Topics: Carotid Artery, Internal, Dissection; Cerebral Angiography; Clopidogrel; Embolization, Therapeutic; Female; Follow-Up Studies; Humans; Intracranial Aneurysm; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Stents; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome	2013
Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention. The American journal of cardiology, 2013, Mar-15, Volume: 111, Issue:6 Topics: Acute Coronary Syndrome; Aspirin; Chi-Square Distribution; Clopidogrel; Endpoint Determination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Statistics, Nonparametric; Thiophenes; Ticlopidine; Treatment Outcome	2013
A pilot study of prasugrel followed by post-procedural maintenance with clopidogrel in patients receiving percutaneous coronary intervention. Journal of interventional cardiology, 2013, Volume: 26, Issue:1 Topics: Aged; Clopidogrel; Female; Humans; Male; Percutaneous Coronary Intervention; Pilot Projects; Piperazines; Platelet Aggregation Inhibitors; Postoperative Care; Prasugrel Hydrochloride; Preoperative Care; Retrospective Studies; Thiophenes; Ticlopidine	2013
Hirudin anticoagulation allows more rapid determination of P2Y₁₂ inhibition by the VerifyNow P2Y12 assay. Thrombosis and haemostasis, 2013, Volume: 109, Issue:3 Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Antithrombins; Area Under Curve; Cations; Citrates; Clopidogrel; Coronary Angiography; Female; Hematologic Tests; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Function Tests; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Sodium Citrate; Thiophenes; Ticlopidine; Treatment Outcome	2013
High on-treatment platelet reactivity (HPR): what does it mean, and does it matter? Thrombosis and haemostasis, 2013, Volume: 109, Issue:2 Topics: Acute Coronary Syndrome; Clopidogrel; Drug Substitution; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine	2013
Prasugrel reduces agonists' inducible platelet activation and leukocyte-platelet interaction more efficiently than clopidogrel. Cardiovascular therapeutics, 2013, Volume: 31, Issue:5 Topics: Aged; Blood Platelets; Cell Communication; Clopidogrel; Female; Humans; Male; Middle Aged; Monocytes; P-Selectin; Peptide Fragments; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2013
Promise and peril of clinical decision support: translating medical evidence to the individual patient. Circulation. Cardiovascular quality and outcomes, 2013, Jan-01, Volume: 6, Issue:1 Topics: Acute Coronary Syndrome; Clopidogrel; Female; Humans; Male; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2013
Antiplatelet efficacy of prasugrel in patients with high on-clopidogrel treatment platelet reactivity and a history of coronary stenting. Thrombosis and haemostasis, 2013, Volume: 109, Issue:3 Topics: Aged; Blood Platelets; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Registries; Thiophenes; Ticlopidine; Treatment Outcome	2013
Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey. Journal of medical economics, 2013, Volume: 16, Issue:4 Topics: Acute Coronary Syndrome; Age Factors; Clopidogrel; Comorbidity; Cost-Benefit Analysis; Europe; Humans; Markov Chains; Models, Economic; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Thiophenes; Ticlopidine; Turkey	2013
Effect of CYP2C192 and 17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications. The American journal of cardiology, 2013, Apr-01, Volume: 111, Issue:7 Topics: Acute Coronary Syndrome; Alleles; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genetic Variation; Genotype; Hemorrhage; Humans; Male; Microfilament Proteins; Middle Aged; Myocardial Infarction; Phosphoproteins; Piperazines; Polymerase Chain Reaction; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticlopidine; Treatment Outcome	2013
Unclassified pleomorphic and spindle cell pulmonary neoplasm with brain metastases after prasugrel. Cardiology, 2013, Volume: 124, Issue:2 Topics: Aged; Aspirin; Brain Neoplasms; Carcinoma; Clinical Trials, Phase III as Topic; Clopidogrel; Colonic Neoplasms; Coronary Stenosis; Diabetes Mellitus, Type 1; Diabetic Cardiomyopathies; Drug Therapy, Combination; Drug-Eluting Stents; Fatal Outcome; Female; Humans; Lung Neoplasms; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticlopidine; Time Factors	2013
Switching acute coronary syndrome patients from prasugrel to clopidogrel. JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:2 Topics: Acute Coronary Syndrome; Aged; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Chi-Square Distribution; Clopidogrel; Drug Resistance; Drug Substitution; Female; Hemorrhage; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Risk Assessment; Risk Factors; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome	2013
Switching from prasugrel to clopidogrel: navigating in unknown waters. JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:2 Topics: Acute Coronary Syndrome; Blood Platelets; Clopidogrel; Drug Substitution; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine	2013
Prasugrel use in a patient allergic to clopidogrel: effect of a drug shortage on selection of dual antiplatelet therapy. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2013, Mar-15, Volume: 70, Issue:6 Topics: Aged; Clopidogrel; Drug Hypersensitivity; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2013
Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. Journal of the American College of Cardiology, 2013, May-21, Volume: 61, Issue:20 Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Patient Selection; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Vitamin K	2013
Tailoring antiplatelet therapy--insanity or good sense? Circulation journal : official journal of the Japanese Circulation Society, 2013, Volume: 77, Issue:5 Topics: Asian People; Clopidogrel; Humans; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2013
Thiolactone sulfoxides as new reactive metabolites acting as bis-electrophiles: implication in clopidogrel and prasugrel bioactivation. Chemical research in toxicology, 2013, May-20, Volume: 26, Issue:5 Topics: Clopidogrel; Cytochrome P-450 Enzyme System; Humans; Lactones; Microsomes, Liver; Molecular Structure; Oxidation-Reduction; Piperazines; Prasugrel Hydrochloride; Prodrugs; Sulfoxides; Thiophenes; Ticlopidine	2013
Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease. Expert review of cardiovascular therapy, 2013, Volume: 11, Issue:4 Topics: Adenosine; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Aspirin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Humans; Pharmacogenetics; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2013
[Your patient needs antithrombotics, 2. What do the new substances offer? (interview by Dr. med. Peter Stiefelhagen)]. MMW Fortschritte der Medizin, 2013, Feb-21, Volume: 155, Issue:3 Topics: Adenosine; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Clopidogrel; Dabigatran; Fibrinolytic Agents; Guideline Adherence; Humans; Morpholines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Ticagrelor; Ticlopidine; Treatment Outcome	2013
Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome. Cardiology, 2013, Volume: 124, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Pressure; Case-Control Studies; Clopidogrel; Endothelium, Vascular; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Peripheral Arterial Disease; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2013
Preserved thrombin-inducible platelet activation in thienopyridine-treated patients. European journal of clinical investigation, 2013, Volume: 43, Issue:7 Topics: Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Female; Humans; Integrin beta3; Male; Middle Aged; P-Selectin; Peptide Fragments; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Membrane Glycoprotein IIb; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Thrombin; Ticlopidine	2013
Cytochrome P450 2B6 and 2C9 genotype polymorphism--a possible cause of prasugrel low responsiveness. Thrombosis and haemostasis, 2013, Volume: 110, Issue:1 Topics: Aryl Hydrocarbon Hydroxylases; Aspirin; Biomarkers, Pharmacological; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C9; Drug Resistance; Drug Therapy, Combination; Female; Gene Frequency; Genetic Association Studies; Genotype; Humans; Male; Middle Aged; Piperazines; Polymorphism, Genetic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine	2013
Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome. The American journal of cardiology, 2013, Aug-01, Volume: 112, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cohort Studies; Cost-Benefit Analysis; Decision Trees; Dose-Response Relationship, Drug; Drug Costs; Drug Therapy, Combination; Drugs, Generic; Female; Humans; Male; Markov Chains; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Quality-Adjusted Life Years; Receptors, Purinergic P2Y12; Survival Rate; Thiophenes; Ticagrelor; Ticlopidine	2013
[Interview with the Daiichi-Sankyo managing director Ralf Göddertz (interview by Dirk Einecke and Cornelius Heyer)]. MMW Fortschritte der Medizin, 2013, Apr-18, Volume: 155, Issue:7 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost Savings; Cost-Benefit Analysis; Drug Costs; Drug Industry; Drugs, Generic; Forecasting; Germany; Humans; National Health Programs; Patents as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2013
ED administration of thienopyridines in non-ST-segment elevation myocardial infarction: results from the NCDR. The American journal of emergency medicine, 2013, Volume: 31, Issue:7 Topics: Aged; Clopidogrel; Drug Administration Schedule; Emergency Service, Hospital; Female; Hemorrhage; Hospital Mortality; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Registries; Retrospective Studies; Thiophenes; Ticlopidine; Treatment Outcome	2013
Viewpoint: mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes. Thrombosis and haemostasis, 2013, Volume: 110, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Europe; Evidence-Based Medicine; Guideline Adherence; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; United States	2013
Differences between ACC/AHA and ESC Guidelines on antiplatelet therapy in patients with acute coronary syndromes. Thrombosis and haemostasis, 2013, Volume: 110, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Europe; Evidence-Based Medicine; Guideline Adherence; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; United States	2013
The impact of the environment on diseases and drugs. Journal of the American College of Cardiology, 2013, Aug-06, Volume: 62, Issue:6 Topics: Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Smoking; Thiophenes; Ticlopidine	2013
Predictors of bleeding in acute coronary syndromes with clopidogrel and prasugrel. The American journal of emergency medicine, 2013, Volume: 31, Issue:8 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Follow-Up Studies; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticlopidine	2013
Predictors of myocardial infarction after an acute coronary syndrome with clopidogrel and prasugrel. The American journal of emergency medicine, 2013, Volume: 31, Issue:8 Topics: Acute Coronary Syndrome; Clopidogrel; Follow-Up Studies; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticlopidine	2013
Gastrointestinal adverse events after dual antiplatelet therapy: clopidogrel is safer than ticagrelor, but prasugrel data are lacking or inconclusive. Cardiology, 2013, Volume: 126, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chemical and Drug Induced Liver Injury; Clinical Trials, Phase III as Topic; Clopidogrel; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Humans; Kaplan-Meier Estimate; Male; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine	2013
Erosive arthritis and hepatic granuloma formation induced by peptidoglycan polysaccharide in rats is aggravated by prasugrel treatment. PloS one, 2013, Volume: 8, Issue:7 Topics: Animals; Arthritis, Experimental; Clopidogrel; Cytokines; Female; Granuloma; Inflammation; Joints; Liver; Peptidoglycan; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Rats; Rats, Inbred Lew; Thiophenes; Ticlopidine	2013
Effectiveness of switching 'hyper responders' from Prasugrel to Clopidogrel after acute coronary syndrome: the POBA (Predictor of Bleeding with Antiplatelet drugs) SWITCH study. International journal of cardiology, 2013, Oct-12, Volume: 168, Issue:5 Topics: Acute Coronary Syndrome; Clopidogrel; Drug Substitution; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome	2013
Sequential value-of-information assessment for prospective drug safety monitoring using claims databases: the comparative safety of prasugrel v. clopidogrel. Medical decision making : an international journal of the Society for Medical Decision Making, 2013, Volume: 33, Issue:7 Topics: Clopidogrel; Drug Monitoring; Humans; Insurance Claim Review; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Thiophenes; Ticlopidine	2013
Identification of poor response to P2Y12 inhibitors in ACS patients with a new ELISA-based vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation assay. Thrombosis and haemostasis, 2013, Volume: 110, Issue:5 Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Cell Adhesion Molecules; Cell Separation; Clopidogrel; Enzyme-Linked Immunosorbent Assay; Feasibility Studies; Female; Flow Cytometry; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Piperazines; Platelet Function Tests; Prasugrel Hydrochloride; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Thiophenes; Ticlopidine	2013
A comparative study of bivalirudin plus clopidogrel versus bivalirudin plus prasugrel in primary angioplasty using propensity score matching. Journal of interventional cardiology, 2013, Volume: 26, Issue:5 Topics: Angioplasty; Antithrombins; Clopidogrel; Cohort Studies; Drug Combinations; Female; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Piperazines; Postoperative Complications; Prasugrel Hydrochloride; Recombinant Proteins; Retrospective Studies; Thiophenes; Thrombosis; Ticlopidine	2013
TRILOGY ACS: prasugrel of benefit only after angiography? Lancet (London, England), 2013, Aug-17, Volume: 382, Issue:9892 Topics: Angina, Unstable; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2013
Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs). JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:8 Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Area Under Curve; Biomarkers; Cell Adhesion Molecules; Clopidogrel; Coronary Thrombosis; Drug Resistance; Female; Hemorrhage; Humans; Logistic Models; Male; Microfilament Proteins; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Phosphoproteins; Phosphorylation; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Risk Assessment; Risk Factors; ROC Curve; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome	2013
Bleeding and thrombosis risk matters: how long can we stick to the one-size-fits-all strategy of platelet inhibition? JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:8 Topics: Acute Coronary Syndrome; Clopidogrel; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2013
Antiplatelet effect of thienopyridine (clopidogrel or prasugrel) pretreatment in patients undergoing primary percutaneous intervention for ST elevation myocardial infarction. The American journal of cardiology, 2013, Nov-15, Volume: 112, Issue:10 Topics: Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Pyridines; Thiophenes; Ticlopidine; Treatment Outcome	2013
Contributions of intestine and plasma to the presystemic bioconversion of vicagrel, an acetate of clopidogrel. Pharmaceutical research, 2014, Volume: 31, Issue:1 Topics: Acetates; Animals; Clopidogrel; Esterases; Humans; Hydrolysis; Intestinal Mucosa; Microsomes; Phenylacetates; Prodrugs; Rats; Rats, Sprague-Dawley; Thiophenes; Ticlopidine	2014
Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting. Cardiovascular drugs and therapy, 2014, Volume: 28, Issue:1 Topics: Anticoagulants; Aspirin; Atrial Fibrillation; China; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; Models, Economic; Morpholines; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Ticlopidine; Warfarin	2014
Comparison of the degree of platelet aggregation inhibition with prasugrel versus clopidogrel and clinical outcomes in patients with unprotected left main disease treated with everolimus-eluting stents. The American journal of cardiology, 2013, Dec-15, Volume: 112, Issue:12 Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Everolimus; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Sirolimus; Thiophenes; Ticlopidine; Treatment Outcome	2013
Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry. Thrombosis and haemostasis, 2014, Volume: 111, Issue:2 Topics: Adenosine; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Drug Design; Female; Germany; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2014
Impact of obesity and the metabolic syndrome on response to clopidogrel or prasugrel and bleeding risk in patients treated after coronary stenting. The American journal of cardiology, 2014, Jan-01, Volume: 113, Issue:1 Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Incidence; Male; Metabolic Syndrome; Middle Aged; Obesity; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Stents; Thiophenes; Ticlopidine; United States	2014
Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention. Circulation. Cardiovascular quality and outcomes, 2013, Volume: 6, Issue:6 Topics: Acute Coronary Syndrome; Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Biotransformation; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Substitution; Female; Genetic Testing; Genotype; Health Personnel; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Postoperative Complications; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Sequence Deletion; Thiophenes; Ticlopidine	2013
Drug interactions with good old clopidogrel: case closed. JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:12 Topics: Acute Coronary Syndrome; Calcium Channel Blockers; Clopidogrel; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2013
'VASPFix' for measurement of VASP phosphorylation in platelets and for monitoring effects of P2Y12 antagonists. Thrombosis and haemostasis, 2014, Mar-03, Volume: 111, Issue:3 Topics: Adenosine; Adenosine Diphosphate; Alprostadil; Biomarkers, Pharmacological; Blood Platelets; Bucladesine; Cell Adhesion Molecules; Cells, Cultured; Clopidogrel; Cyclic AMP; Humans; Iloprost; Microfilament Proteins; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Reproducibility of Results; Sensitivity and Specificity; Thiophenes; Thrombophilia; Ticlopidine	2014
In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prevalence, predictors and short-term outcome. American heart journal, 2014, Volume: 167, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Piperazines; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2014
Antiplatelet therapy in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: a retrospective observational study of prasugrel and clopidogrel. Cardiovascular therapeutics, 2014, Volume: 32, Issue:1 Topics: Adult; Aged; Clopidogrel; Electrocardiography; Female; Hospital Mortality; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Retrospective Studies; Thiophenes; Ticlopidine	2014
Association of thrombin generation potential with platelet PAR-1 regulation and P-selectin expression in patients on dual antiplatelet therapy. Journal of cardiovascular translational research, 2014, Volume: 7, Issue:1 Topics: Adult; Aged; Aspirin; Biomarkers; Blood Platelets; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; P-Selectin; Peptide Fragments; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prothrombin; Receptor, PAR-1; Thiophenes; Thrombin; Ticlopidine	2014
Smoking status and the effects of antiplatelet drugs. BMJ (Clinical research ed.), 2013, Oct-01, Volume: 347 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Smoking; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2013
Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. Journal of the American College of Cardiology, 2014, Mar-25, Volume: 63, Issue:11 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Combined Modality Therapy; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Risk Assessment; Severity of Illness Index; Stents; Stroke; Survival Rate; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome	2014
Near-real-time monitoring of new drugs: an application comparing prasugrel versus clopidogrel. Drug safety, 2014, Volume: 37, Issue:3 Topics: Aged; Clopidogrel; Cohort Studies; Databases, Factual; Electronic Health Records; Female; Hemorrhage; Humans; Ischemia; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Product Surveillance, Postmarketing; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine	2014
High rates of prasugrel and ticagrelor non-responder in patients treated with therapeutic hypothermia after cardiac arrest. Resuscitation, 2014, Volume: 85, Issue:5 Topics: Adenosine; Clopidogrel; Female; Flow Cytometry; Heart Arrest; Humans; Hypothermia, Induced; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2014
Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis. The American journal of emergency medicine, 2014, Volume: 32, Issue:5 Topics: Aged, 80 and over; Aspirin; Clopidogrel; Coronary Angiography; Diabetes Mellitus, Type 2; Drug Resistance; Electrocardiography; Heparin; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Thrombosis; Ticlopidine	2014
DTB Select: 3 \| March 2014. Drug and therapeutics bulletin, 2014, Volume: 52, Issue:3 Topics: Alzheimer Disease; Antibodies, Monoclonal, Murine-Derived; Automobile Driving; Child; Chronic Pain; Clopidogrel; Hepatitis B; Histamine H2 Antagonists; Humans; Hypertension; Practice Guidelines as Topic; Practice Patterns, Physicians'; Proton Pump Inhibitors; Respiratory Tract Infections; Rituximab; Thiophenes; Ticlopidine	2014
Safer heart-attack prevention for seniors with revised drug regimen. Half the normal dose of prasugrel, a lifesaving medication, is just as effective as the larger dose, and reduces risk of serious side effects. DukeMedicine healthnews, 2013, Volume: 19, Issue:11 Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Secondary Prevention; Thiophenes; Ticlopidine	2013
Transient receptor potential ankyrin 1 (TRPA1) channel activation by the thienopyridine-type drugs ticlopidine, clopidogrel, and prasugrel. Cell calcium, 2014, Volume: 55, Issue:4 Topics: Calcium; Calcium Channels; Cell Line; Clopidogrel; Enterochromaffin-like Cells; Gene Expression Regulation; HEK293 Cells; Humans; Mutation; Nerve Tissue Proteins; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Serotonin; Thiophenes; Ticlopidine; Time-Lapse Imaging; Transient Receptor Potential Channels; TRPA1 Cation Channel	2014
A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry. Thrombosis and haemostasis, 2014, Volume: 112, Issue:2 Topics: Aged; Aged, 80 and over; Blood Platelets; Case-Control Studies; Clopidogrel; Coronary Thrombosis; Drug Resistance; Drug Substitution; Female; Germany; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Risk Factors; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome	2014
Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. Annals of internal medicine, 2014, Feb-18, Volume: 160, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Alleles; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Thrombosis; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Support Techniques; Direct Service Costs; Drug Therapy, Combination; Drugs, Generic; Genotype; Hemorrhage; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Quality-Adjusted Life Years; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine	2014
Controversies in acute cardiovascular care. European heart journal, 2014, Volume: 35, Issue:9 Topics: Adenosine; Clinical Trials as Topic; Clopidogrel; Emergency Medical Services; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2014
Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry. Journal of the American Heart Association, 2014, Apr-14, Volume: 3, Issue:2 Topics: Aged; Clopidogrel; Drug Administration Schedule; Drug Utilization Review; Female; Guideline Adherence; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Retrospective Studies; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome; United States	2014
Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery. European heart journal, 2014, Jun-14, Volume: 35, Issue:23 Topics: Adenosine; Aspirin; Blood Platelets; Clopidogrel; Consensus; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Postoperative Care; Prasugrel Hydrochloride; Preoperative Care; Purinergic P2Y Receptor Antagonists; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine	2014
Triple antithrombotic therapy: risky but sometimes necessary. Revista espanola de cardiologia (English ed.), 2014, Volume: 67, Issue:3 Topics: Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clopidogrel; Dabigatran; Drug Therapy, Combination; Humans; Morpholines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticlopidine; Vitamin K	2014
Is it appropriate to compare the results from two clinical trials with one drug in common? Revista espanola de cardiologia (English ed.), 2013, Volume: 66, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine	2013
Viewpoint: "underutilisation of novel antiplatelet agents--myths, generics, and economics". Thrombosis and haemostasis, 2014, Jul-03, Volume: 112, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combination; Drug Utilization; Evidence-Based Medicine; Humans; Japan; Marketing; Piperazines; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine	2014
There's life in the old dog yet: clopidogrel competing with prasugrel and ticagrelor for treatment of ACS patients. Thrombosis and haemostasis, 2014, Jul-03, Volume: 112, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Drug Substitution; Drug Therapy, Combination; Economic Competition; Humans; Piperazines; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2014
Utilisation of novel anti-platelet agents: evidence, guidelines and proven patients' value. Thrombosis and haemostasis, 2014, Jul-03, Volume: 112, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Costs and Cost Analysis; Drug Utilization; Evidence-Based Medicine; Humans; International Cooperation; Marketing; Patient Satisfaction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine	2014
Switching patients from clopidogrel to novel P2Y12 receptor inhibitors in acute coronary syndrome: comparative effects of prasugrel and ticagrelor on platelet reactivity. International journal of cardiology, 2014, Jul-01, Volume: 174, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Drug Substitution; Female; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2014
Prasugrel increases the need for platelet transfusions and surgical reexploration rates compared with clopidogrel in coronary artery bypass surgery. The Thoracic and cardiovascular surgeon, 2015, Volume: 63, Issue:1 Topics: Anticoagulants; Clopidogrel; Coronary Artery Bypass; Forecasting; Humans; Logistic Models; Piperazines; Platelet Transfusion; Postoperative Hemorrhage; Prasugrel Hydrochloride; Preoperative Period; Purinergic P2Y Receptor Antagonists; Reoperation; Thiophenes; Ticlopidine	2015
Improving outcomes with bivalirudin in primary percutaneous coronary intervention. European heart journal, 2014, Sep-07, Volume: 35, Issue:34 Topics: Anticoagulants; Clopidogrel; Heparin; Hirudins; Humans; Male; Myocardial Infarction; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recombinant Proteins; Thiophenes; Ticlopidine	2014
Resolution of clopidogrel-associated polyarthritis after conversion to prasugrel. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2014, Jul-01, Volume: 71, Issue:13 Topics: Aged; Arthritis; Clopidogrel; Humans; Male; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine	2014
Uncovering the shroud on antiplatelet therapy for patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. JACC. Cardiovascular interventions, 2014, Volume: 7, Issue:6 Topics: Clopidogrel; Electrocardiography; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Thiophenes; Thrombolytic Therapy; Ticlopidine	2014
Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States. Current medical research and opinion, 2014, Volume: 30, Issue:11 Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Stroke; Thiophenes; Ticlopidine; Treatment Outcome; United States	2014
In-hospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the national cardiovascular data registry. Circulation. Cardiovascular interventions, 2014, Volume: 7, Issue:4 Topics: Acute Disease; Age Factors; Aged; Clopidogrel; Drug Substitution; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Postoperative Complications; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Recurrence; Registries; Risk Factors; Thiophenes; Thrombosis; Ticlopidine; United States	2014
Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without increasing bleeding risk. Science translational medicine, 2014, Aug-06, Volume: 6, Issue:248 Topics: Adenosine Diphosphate; Animals; Apyrase; Clopidogrel; Coronary Circulation; Dogs; Fibrinolysis; Hemorrhage; Humans; Mice, Inbred C57BL; Myocardial Infarction; Myocardial Reperfusion Injury; Piperazines; Platelet Aggregation; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Thrombosis; Ticlopidine; Time Factors; Tissue Plasminogen Activator; Treatment Outcome; Vascular Patency	2014
Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. Results of the ISAR-SHOCK registry. Thrombosis and haemostasis, 2014, Volume: 112, Issue:6 Topics: Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Coronary Thrombosis; Female; Germany; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Recurrence; Registries; Risk Factors; Shock, Cardiogenic; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome	2014
Prasugrel vs. clopidogrel in acute coronary syndrome patients treated with prasugrel. Journal of clinical pharmacy and therapeutics, 2014, Volume: 39, Issue:6 Topics: Acute Coronary Syndrome; Aged; Bayes Theorem; Clopidogrel; Cohort Studies; Female; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Retrospective Studies; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome	2014
Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry. BMJ open, 2014, Oct-31, Volume: 4, Issue:10 Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Coronary Artery Disease; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Prospective Studies; Registries; Stents; Thiophenes; Ticagrelor; Ticlopidine	2014
Dual antiplatelet therapy after drug-eluting stents--how long to treat? The New England journal of medicine, 2014, Dec-04, Volume: 371, Issue:23 Topics: Aspirin; Clopidogrel; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine	2014
Point-of-care platelet reactivity determination with VerifyNow-P2Y12 following administration of clopidogrel or prasugrel: data from a real-world, clinical care inpatient setting. Hospital practice (1995), 2014, Volume: 42, Issue:4 Topics: Aged; Clopidogrel; Electronic Health Records; Female; Hospitalization; Hospitals, Urban; Humans; Logistic Models; Male; Medical Audit; Middle Aged; Piperazines; Platelet Aggregation; Point-of-Care Systems; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2014
A pharmacodynamic comparison of 5 anti-platelet protocols in patients with ST-elevation myocardial infarction undergoing primary PCI. BMC cardiovascular disorders, 2014, Dec-16, Volume: 14 Topics: Adenosine; Aged; Blood Platelets; Clinical Protocols; Clopidogrel; Drug Administration Schedule; Electrocardiography; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Thiophenes; Ticagrelor; Ticlopidine	2014
World heart federation expert consensus statement on antiplatelet therapy in east asian patients with ACS or undergoing PCI. Global heart, 2014, Volume: 9, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Asia, Eastern; Cardiology; Clopidogrel; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Societies, Medical; Thiophenes; Ticagrelor; Ticlopidine; World Health Organization	2014
Investigation of possible prophylactic, renoprotective, and cardioprotective effects of thromboprophylactic drugs against ischemia-reperfusion injury. The Kaohsiung journal of medical sciences, 2015, Volume: 31, Issue:3 Topics: Animals; Anticoagulants; Aryldialkylphosphatase; Aspirin; Cardiotonic Agents; Clopidogrel; Dipeptidases; Drug Evaluation, Preclinical; Enoxaparin; Femoral Artery; Heparin, Low-Molecular-Weight; Hindlimb; Kidney; Male; Malondialdehyde; Morpholines; Myocardium; Nitric Oxide; Oxidative Stress; Rats, Sprague-Dawley; Reperfusion Injury; Rivaroxaban; Thiophenes; Ticlopidine	2015
Predictors of high on-aspirin platelet reactivity in high-risk vascular patients treated with single or dual antiplatelet therapy. The American journal of cardiology, 2015, May-01, Volume: 115, Issue:9 Topics: Adenosine; Aged; Aspirin; Cerebrovascular Disorders; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Fibrinogen; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Secondary Prevention; Thiophenes; Ticagrelor; Ticlopidine	2015
Synthesis of the alkylated active metabolite of tipidogrel. Bioorganic & medicinal chemistry letters, 2015, Apr-15, Volume: 25, Issue:8 Topics: Alkylation; Animals; Chromatography, High Pressure Liquid; Clopidogrel; Half-Life; Piperidines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Pyridines; Rats; Receptors, Purinergic P2Y12; Tandem Mass Spectrometry; Thiophenes; Ticlopidine	2015
Significant Improvement of Metabolic Characteristics and Bioactivities of Clopidogrel and Analogs by Selective Deuteration. Molecules (Basel, Switzerland), 2016, May-30, Volume: 21, Issue:6 Topics: Adenosine Diphosphate; Animals; Clopidogrel; Hydrolysis; Male; Metabolic Networks and Pathways; Models, Molecular; Molecular Conformation; Phenylacetates; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats; Thiophenes; Ticlopidine	2016
A Pharmacodynamic Study of CN-218, a Novel Antiplatelet and Antithrombotic Agent Primarily Targeting the P2Y Cardiovascular drugs and therapy, 2020, Volume: 34, Issue:1 Topics: Animals; Blood Coagulation; Blood Platelets; Carrageenan; Clopidogrel; Cyclic AMP; Disease Models, Animal; Fibrinolytic Agents; Hemorrhage; Male; Mice; Piperidines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Rats, Wistar; Receptors, Purinergic P2Y12; Thiophenes; Thrombosis	2020
Pharmacokinetics, mass balance, and metabolism of [ Acta pharmacologica Sinica, 2021, Volume: 42, Issue:9 Topics: Administration, Oral; Adult; Clopidogrel; Humans; Male; Phenylacetates; Purinergic P2Y Receptor Antagonists; Thiophenes	2021
Evaluation of efficacy and safety after replacement of methyl hydrogen with deuterium at methyl formate of Clopidogrel. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2022, May-01, Volume: 172 Topics: Clopidogrel; Deuterium; Formic Acid Esters; Hydrogen; Molecular Docking Simulation; Platelet Aggregation; Platelet Aggregation Inhibitors; Thiophenes	2022
Semi-mechanistic population pharmacokinetics analysis reveals distinct CYP2C19 dependency in the bioactivation of vicagrel and clopidogrel to active metabolite M15-2. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2022, Oct-01, Volume: 177 Topics: Clopidogrel; Cytochrome P-450 CYP2C19; Galanin; Humans; Phenylacetates; Platelet Aggregation Inhibitors; Substance P; Thiophenes; Ticlopidine	2022
Several non-salt and solid thienopyridine derivatives as oral P2Y Bioorganic & medicinal chemistry letters, 2022, 11-01, Volume: 75 Topics: Clopidogrel; Cytochrome P-450 CYP2C19; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thienopyridines; Thiophenes	2022